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1. OUTLINE 
 
Declining fertility is a major obstacle in maintaining profitability of dairy farms [1-3]. 
One likely cause of the reduced fertility is that over the past 30 years breeding schemes 
have almost solely been based on selecting traits for high milk production. This has likely 
resulted in alterations in a large number of genes that adversely affect fertility [2, 3]. For 
this reason there is an urgent need to identify the genes that are responsible for the 
reduced fertility in diary cattle. This would immediately lead to advancement in the 
management practices in breeding programs and could improve the reproductive 
performance of high milk-producing dairy cows.  
Progesterone receptor membrane component 1 (PGRMC1) belongs to the membrane-
associated progesterone receptor (MAPR) proteins family involved in regulating numerous 
biological functions [4]. PGRMC1 is mainly localized in intracellular membranes and 
colocalizes with the endoplasmic reticulum and Golgi apparatus in rat liver cells and 
hippocampal Pukinje cells. However, several studies described a nuclear or chromosomal 
localization. Several reports suggest the participation PGRMC1 in progesterone signaling 
in the reproductive system in different mammalian species. PGRMC1 has been detected 
in nuclear extracts of HeLa cells among the protein of the human mitotic spindles, in 
oocyte nucleus and recently has been proposed in regulating microtubule stability in 
human and rat ovarian cell mitosis [5]. Interestingly, deletion and point mutations of 
PGRMC1 have been associated with human premature ovarian failure (POF) [6]. 
Moreover, defects in spindle formation and/or function can generate chromosome 
instability and aneuploidy, a condition that is the major cause of defective early embryonic 
development, miscarriages and birth defects [7]. In humans, the frequency of aneuploidy  
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increases with female age, with the decline of ovarian function, the gradual depletion of 
ovarian follicle reserve and the reduced ability to produce oocytes competent for 
fertilization and embryo development [8]. However, this occurs also in young infertile and 
subfertile women affected by POF [9, 10].  
Because of the possible relevance in reproductive function, the present study was 
undertaken in order to clarify the role of PGRMC1 in bovine reproductive system and 
ovarian function. Finally, since we recently demonstrated that about 5% of individuals in 
the current population of culled dairy cows 4-8 years old is affected by a significant 
reduction of follicles population [11] this study analyzed the possible involvement of 
PGRMC1 in cow infertility and in reproduction in mammals. 
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2. INTRODUCTION AND HISTORY OF PGRMC1 AND SUB-CELLULAR 
LOCALIZATION 
Progesterone receptor membrane component 1 (PGRMC1) belongs to the so-
called membrane-associated progesterone receptor (MAPR) protein family that is 
widespread in eukaryotes [4]. The protein now termed PGRMC1 was cloned in 1996 as a 
membrane progesterone receptor from a porcine cDNA library by Falkenstein et al. after 
the N-terminal amino acid sequence had been determined [12]. In the same year, Selmin 
et al. reported the DNA sequence of a gene whose expression was induced in rat liver 
upon treatment with 2,3,7,8-tetrachloro dibenzodioxine (TCDD) and termed 25-Dx [13]. 
The human homolog (Hpr6) of porcine membrane progesterone receptor was identified in 
1998, and the gene was localized to the X chromosome [14]. PGRMC1 was recognized 
as an immunologically defined antigen that had been named inner zone antigen (IZA), 
localised in the zona fasciculata and reticularis of the adrenal cortex [15]. PGRMC1 
expression had been observed also during embryogenesis of the mouse spinal cord and 
optic chiasm, suggesting an important role in regulating axon guidance at the midline of 
the developing embryonic central nervous system [16]. In 2004 the same authors 
identified a lower eukaryotic PGRMC1 homolog VEM-1 in Caenorhabditis elegans 
nematode. By a transgenic null mutation it was demonstrated that VEM-1 was involved in 
neuron guidance and axon formation in the nematode ventral midline, which was the 
context that had led to the identification of mammalian previous study [17]. In unicellular 
eukaryotes as Saccharomices cerevisae yeast, PGRMC1 homolog, named Dap1 
(damage-associated protein), has been found to interact with cytochrome P450 proteins to 
synthesize sterols and protect cells from DNA damage [18, 19]. In conclusion 
phylogenetic tree construction based upon similarity of sequences of PGRMC1-related 
members of the MAPR family shows a wide eukaryotic distribution [4].  
PGRMC1 was first purified from rat liver (microsomal) membrane fractions [20], and was 
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shown to cofractionate with the endoplasmic reticulum in liver extracts [21]. Perinuclear 
localization, consistent with endoplasmic reticulum, was observed in MCF-7 cells [22]. 
Two more reports suggest a nuclear or chromosomal localisation for PGRMC1. Beausoleil 
et al. detected phosphopeptides from PGRMC1 in nuclear extracts of HeLa cells [23], and 
Sauer et al. detected phosphorylated PGRMC1 in extracts of human mitotic spindles [24]. 
Raza et al. [15] observed a 28 kDa isoform in microsomal and mitochondrial fractions, 
whereas the 58 kDa form was observed in the cytosolic fraction of rat adrenal inner zones. 
In 2005 Min et al. observed that rIZA1 was distributed diffusely in the cell, forming 
vesicular structures suggesting its association with the membrane compartments, and 
colocalising with cytochrome b5 of the endoplasmic reticulum in HeLa cells [25]. Immune 
histochemistry studies on neonatal hippocampal Pukinje cells also suggested an 
endoplasmic reticulum and Golgi apparatus distribution [26]. 
At least some fractions of the PGRMC1 in spontaneously immortalized granulosa cells 
(SIGCs) were available for biotinylation on the surface of non-permeabilised cells [27, 28]. 
PGRMC1 was also one of the proteins that was detected after the biotinylation of 
extracellular proteins in various cancer cell lines by Shin et al. in 2003, in a study that 
revealed the presence of various topologically ‘cytoplasmic’ proteins in the extracellular 
compartment [29]. It is worthy of mention here that the distantly related Neudesin MAPR 
family member was identified as an extracellular mediator of neurotropic (anti neuro-
apoptotic) responses, including the regulation of proliferation and differentiation decisions 
in the central nervous system [30, 31], suggesting that the cytochrome b5 domain of 
PGRMC1 could also induce specific extracellular responses if externalized, perhaps by 
mediating intercellular steroid transport. Sperm seem also to possess PGRMC1 on the 
cell surface because an antibody to the N-terminal region could specifically block the 
progesterone-driven acrosome reaction that accompanies sperm fusion with the egg upon 
fertilisation [32, 33]. However, it is unclear from the above studies whether this 
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extracellular PGRMC1 component constitutes a major or minor fraction of the total 
PGRMC1 localised to those respective cells. 
Progesterone treatment of spinal chord-injured rats led to increased PGRMC1 expression, 
and the protein was immunolocalized on the cell membranes of dorsal horn and central 
canal neurons [34]. Bramley et al. reported co-precipitation of PGRMC1 with an antisera 
to caveolin [35], and this was dependent upon the use of the cholesterol-chelating reagent 
digitonin (see section on Potential Ligands). Failure to detect PGRMC1 
immunofluorescence except in permeabilized cells in the developing CNS of rodent 
embryos [16] suggested that: “PGRMC1 is associated exclusively with intracellular 
membranes or that it only transiently resides at the cell surface before being cleared, 
possibly, via endocytosis” [36]. Munton et al. observed a fifteen fold higher relative 
abundance of PGRMC1 in a murine brain subcellular post-synaptic density fraction than 
from synaptic membranes. Intriguingly, tyrosine-phosphorylated PGRMC1 was only 
detected in the synaptosomal preparation rather than in preparations of synaptic vesicles 
or postsynaptic density [37]. 
The HC5 protein, corresponding essentially to the truncated N-terminus of PGRMC1 
including the transmembrane domain, nevertheless, does not seem to be located at the 
membrane level because an antibody generated to this region, detected a 10 kDa protein 
in liver cytosolic but not microsomal fractions, as mentioned above. The anti HC5 antibody 
and IZA monoclonal antibody, recognized 28 and 25 kDa proteins in microsomal fractions, 
yet only a 25 kDa protein in cytosolic fractions, suggesting that PGRMC1 may alternate 
between membrane-bound and cytosolic forms [38]. 
In their 2004 review, Min et al. suggest that PGRMC1 “might form multimers via a 
reducing reagent resistant bond, and the change from monomer to multimer might result 
in changes in intracellular distribution of these molecules and also of their functions” [39]. 
Therefore it is probably prudent to assume that PGRMC1 can alter its sub-cellular location 
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under certain circumstances, which are as yet poorly understood, and that this 
redistribution could be important for PGRMC1-directed biological processes. Indeed it is 
difficult to avoid the conclusion that the key to unraveling the role of PGRMC1 lies in 
understanding the regulation of its function in various sub-and extra-cellular 
compartments. It also remains unclear whether only the N-terminus up to the 
transmembrane domain can be extracellular and available for biotinylation, or whether the 
entire protein may be translocated to the extracellular space. 
 
3. PGRMC1: FUNCTIONS AND POTENTIAL LIGANDS 
 
PGRMC1 has been implicated in the binding of several ligands, all of which could yet 
prove to be of biological relevance. 
3.1 PGRMC1 and Progesterone/steroids 
PGRMC1 was initially cloned in search of membrane receptors for progesterone that were 
distinct from the classical hormone activated PR transcription factor. Meyer et al. [20] 
showed that swine liver microsomes have a high affinity (kd = 11 nM) and a low affinity 
(kd= 286 nM) binding site for progesterone. In a 2006 paper these authors referred to this 
as the approximate kd of PGRMC1 for progesterone, citing the data from the 1996 paper: 
“Interestingly the kd for PGRMC1 is in the 0.2 to 0.3 µM range” [28], however the actual 
molecular identity of the progesterone receptor in microsomes was not formally proven. 
The major binding activity was purified, and the fraction with most activity contained the 28 
and 56 kDa proteins that have already been described above, and which led to the cloning 
of porcine and later human PGRMC1. However there were undoubtedly many other 
additional proteins in this fraction. An antibody against the N-terminal peptide recognized 
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28 and 56 kDa bands that could be competed by that peptide, in a protein complex that 
was approximately 200 kDa as estimated by size exclusion chromatography [40]. 
Falkenstein et al., from the Mannheim group, showed in 1999 [33] and in 2001 [41] that 
pig liver microsomes bind progesterone as a radio-ligand, and that the binding form 
consisted of a higher order complex containing at least two molecules of the 28 kDa 
PGRMC1 monomer. When excess PGRMC1 was introduced by transfecting an 
expression plasmid, the progesterone binding activity of the microsomal fractions 
increased [33]. Yet it is possible that PGRMC1 caused the induction or permissive 
modification of another progesterone binding protein. Using selective chemical 
modification of amino acids, they concluded that progesterone binding required carboxyl, 
methionine and tryptophan groups [41]. However possible allosteric effects on protein 
structure by these modifications were not adequately controlled, which could mean that 
none of those amino acids actually contacts a bound progesterone ligand. Furthermore, 
those authors only demonstrated a correlation between chemical treatment of microsomes 
and reduced levels of progesterone binding of microsomes, a result that might be 
expected regardless of the identity of the receptor. They did not actually demonstrate that 
the receptor was PGRMC1, which they correctly acknowledged in their discussion. 
Ovarian surface epithelial cells express PGRMC1 and respond to progesterone at doses 
consistent with a low affinity receptor characterized in liver microsomes [28]. Yet 
overexpression of PGRMC1 increased progesterone binding and the responsiveness of 
SIGCs to progesterone’s anti-apoptotic actions. Although an antibody directed against the 
extracellular domain of PGRMC1 blocked progesterone’s capacity to inhibit apoptosis, it 
remains to be demonstrated that the actual receptor of progesterone is not another protein 
such as PAIRBP1, which is co-expressed with PGRMC1 in those cells, and which has 
been observed in a protein complex with PGRMC1. Indeed, this is likely. 
In 2006 Viero et al. suggested that PGRMC1 may mediate the response to neurosteroids 
in murine embryonic sensory neurons, however the only evidence was the demonstration 
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by PCR that PGRMC1 was expressed in the responsive cells [42]. This was consistent 
with the prior work of Sakamoto et al., who observed in 2004 that PGRMC1 is expressed 
in neonatal rat Purkinje cells at precisely the time when they synthesise progesterone 
from cholesterol, and when they respond to that steroid. A variety of previous evidence 
suggested that progesterone acts on Purkinje cells via membrane-associated 
progesterone-binding proteins to promote neonatal dendritic growth, spinogenesis and 
synaptogenesis. Those authors furthermore conclude that: “mifepristone (RU486) protects 
Purkinje cells from developmental cell death (...). Because this protective effect of RU486 
is considered to be independent on the activation of nuclear PRs [i.e., transcription factor 
PR] (...), 25-Dx-mediated [PGRMC1] mechanisms might be involved in the protection of 
Purkinje cells.” [26]. 
It must be noted that none of the studies cited here actually demonstrated progesterone 
binding to PGRMC1, but rather to microsome membranes containing PGRMC1 and 
multiple other proteins, or to progesterone-responsive tissues expressing PGRMC1. 
Biologically relevant binding of progesterone to PGRMC1 still remains to be demonstrated 
under conditions where PGRMC1 might not be complexed with or otherwise influence 
PAIRBP1, leaving open the possibility that PAIRBP1 or another protein(s) provides the 
actual binding activity. Indeed, in 2005 Ghosh et al. [43] could not detect specific 
progesterone binding to purified recombinant PGRMC1, however they did detect heme-
binding under the same conditions. Similarly, Min et al. [25] also failed to observe specific 
progesterone binding to a bacterially expressed purified GST-PGRMC1 (GST-hIZA1) 
fusion protein that reversibly bound heme with modest affinity. Thus, the situation has 
essentially remained unchanged since the original cloning of Hpr6 in 1998, where Gerdes 
et al. stated that: “These correlations provide evidence that the progesterone binding sites 
and the Hpr6.6 proteins are identical or at least localised within the same complex” [14]. 
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3.2 PGRMC1 and cholesterol synthesis 
The cholesterol synthetic pathway is an important target for treating cardiovascular 
disease and inhibiting fungal infections. PGRMC1 likely regulates cholesterol synthesis in 
two ways. First, PGRMC1 binds and activates the P450 protein Cyp51/lanosterol 
demethylase [19], which catalyzes an essential reaction in the sterol synthetic pathway 
[44]. This finding was derived directly from research in the fungi Saccharomyces 
cerevisiae and Schizosaccharomyces pombe, where the PGRMC1 homologue, called 
Dap1, activates Cyp51 [18, 19, 45, 46]. However, Dap1–Cyp51 binding has not been 
demonstrated in S. cerevisiae, and the two proteins only partially overlap in their 
localization [45]. 
Cyp51 is the target for the azole class of antifungal drugs, which are widely used to treat 
yeast infections, and Dap1 mediates resistance to azole drugs by activating Cyp51 [18, 
19, 46]. Dap1 also regulates a second P450 protein, called Erg5, in the cholesterol 
synthetic pathway [18, 19, 46] suggesting a general role for Dap1 in P450 activation. As in 
yeast, human PGRMC1 binds to Cyp51, and human embryonic kidney cells depleted for 
PGRMC1 have a partial arrest in cholesterol synthesis [19]. 
In addition to activating Cyp51, PGRMC1 binds to the proteins Insig (insulin-induced 
gene) and Scap [SREBP cleavage activating protein [47]], which span the endoplasmic 
reticulum and sense cholesterol levels. SREBP (sterol regulatory element binding protein) 
is a transcription factor which exists in a precursor form in the endoplasmic reticulum [19, 
48]. Insig inhibits the processing and activation of SREBP by binding to Scap [48, 49]. 
When Insig is itself inhibited, Scap is released to escort SREBP to the Golgi for 
processing [48]. The biological role of PGRMC1 in regulating Insig and Scap is unclear, 
and whether Insig and Scap are part of the P450 or progesterone-binding complexes 
associated with PGRMC1 is not known. 
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3.3 Interactions between PGRMC1 and P450 proteins 
In yeast and humans, PGRMC1 binds directly to P450 proteins. Dap1 binds to 
Cyp51/lanosterol demethylase in yeast, and PGRMC1 binds to Cyp51, Cyp3A4, 
Cyp7A1/cholesterol 7α-hydroxylase and Cyp21A2/21-hydroxylase in humans [19]. This 
implies a role for PGRMC1 in cholesterol synthesis, drug and hormone metabolism and 
bile acid synthesis. Indeed, monoclonal antibodies to PGRMC1 block the 21-hydroxylation 
of progesterone in rat adrenal tissue [50], and PGRMC1 activates Cyp21 when the two 
proteins are coexpressed [25, 39, 46], indicating that PGRMC1 promotes progesterone 
turnover. As in yeast, human PGRMC1 is required for the Cyp51-catalyzed step in 
cholesterol synthesis [19]. PGRMC1 and its homologues have been likened to “helping 
hands for P450 proteins” [51], and PGRMC1 is highly expressed in the rodent and human 
liver [13-15, 52], suggesting that PGRMC1 may contribute to multiple P450-mediated 
pathways. 
P450 proteins require a reductase partner, and Dap1 (the yeast PGRMC1 homologue) 
has reducing activity [53], suggesting that PGRMC1 class proteins may be more than 
“helping hands”. PGRMC1 is also related to cytochrome b5, an important coactivator of 
numerous P450 reactions [54]. However, Dap1 binds to heme through a penta-coordinate 
mechanism [53], which is distinct from that of cytochrome b5, and hyper-expression of 
cytochrome b5 could not complement loss of the DAP1 gene in yeast [46], suggesting that 
their functions do not overlap. Furthermore, Dap1 has a much higher affinity for ferric 
heme than ferrous heme [53], suggesting that Dap1 would release heme during a redox 
cycle. Thus, the precise mechanism through which Dap1 activates P450 proteins is 
unclear. 
Like Dap1, PGRMC1 binds to heme, although its relative affinity for ferric and ferrous 
heme and its reducing activity have not been determined. The putative structure of 
PGRMC1 from the protein database predicts a prominent groove at the center of the 
protein (Figure 1). The Asp120 residue, which is required for heme binding [55], is at the 
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center of the groove, and a proposed phosphorylation site for the Abl tyrosine kinase [4] is 
located near the opening of the groove (Figure 1, right, the tyrosine residue of the GPY). 
The Tyr164 residue, which corresponds to the yeast Tyr138 site, is required for heme 
binding in S. cerevisiae Dap1 [53] and S. pombe Dap1 [19]. The Tyr107 and Tyr113 
residues (indicated by arrows in the GPY site and adjacent to it) are required for heme 
binding in rat PGRMC1/IZA1 [39], and all of these residues localize to the same central 
groove of Pgrmc1 as Asp120 (Figure 1). Dap1 and PGRMC1 have similar roles in 
cholesterol synthesis and damage resistance, and this is reflected in the conserved 
residues that surround the central groove (Figure 1, conserved residues are indicated by 
asterisks). In this depiction, residues that are different in Dap1 and PGRMC1 cluster at 
one end of the protein and are indicated by pound signs in Figure 1. 
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Figure 1. A model for the structure of residues 71–171 of PGRMC1. Asterisks indicate 
identical residues between PGRMC1 and its yeast homologue, Dap1, while pound signs 
indicate key non-conserved residues. The sequences of the two proteins are shown below 
with the identical sequences shaded in gray. The positions of four residues are indicated 
as a reference point. PGRMC1 residues Asp120, Tyr107, Tyr113 and Tyr164 are required 
for heme binding in PGRMC1, and the residues that are analogous to Asp120 and Tyr164 
are required for heme binding in Dap1 [56]. 
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3.4 PGRMC1 AND CANCER 
 
3.4.1 PGRMC1 expression in clinical tumor samples 
PGRMC1 is over-expressed in breast tumors and in cancer cell lines from the colon, 
thyroid, lung, and cervix [57]. In ovarian cancer, PGRMC1 expression increased in 
advanced stage tumors, and PGRMC1 was homogeneously expressed within the tumors 
[58]. Microarray analyses have also detected PGRMC1 expression in colon, lung, ovarian 
and breast tumors [59-62]. In breast cancer, PGRMC1 is part of a protein signature that 
predicts hypoxia [60], which is reminiscent of its induction during hypoxia in S. pombe 
[19]. Conversely, the PGRMC1 promoter is hypermethylated in ovarian cancer [63]. 
One P450-mediated pathway to which PGRMC1 could contribute is the synthesis and 
metabolism of estrogen and progesterone. Both hormones are synthesized from 
cholesterol via steps requiring multiple P450 proteins, including P450scc (Cyp11A1), 
Cyp17 and Cyp19 (aromatase). Estrogen (E2 and E1) is hydroxylated by Cyp1A1, 
Cyp1A2, Cyp3A4 and Cyp1B1 to form active metabolites 2-hydroxyestradiol (2-OH-E2) 
and 4-hydroxyestradiol (4-OH-E2). Both 2-OH-E2 and 4-OH-E2 are further oxidized into 
carcinogenic compounds estrogen-2,3-quinone and estrogen-3,4-quinone [64, 65]. While 
it is intriguing to speculate whether PGRMC1 could contribute to hormone synthesis, 
signaling and turnover, its biological role in these pathways remains to be elucidated. 
 
3.4.2 A six gene carcinogenicity signature includes PGRMC1 
PGRMC1 is also implicated as a biomarker in other steps in cancer progression. Nie, et 
al. identified a carcinogenicity signature in rats, which included PGRMC1 and five other 
genes, in response to 52 known carcinogenic compounds [66]. Hokaiwado, et al. 
performed a similar analysis and identified PGRMC1, among others [67]. PGRMC1 was 
originally cloned as 25-Dx based on its induction by the non-genotoxic carcinogen 2,3,7,8-
tetrachlorodibenzop-dioxin in the rat liver [13], which also induces P450 proteins such as 
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Cyp1A1 [68]. It is unclear how P450 proteins like Cyp1A1 trigger tumor formation, 
although P450-mediated oxidative damage is a candidate mechanism [69]. It is notable 
that human PGRMC1 promotes cell death in cancer cells after oxidative damage [22], 
possibly due to its activation of P450 proteins, activates the pro-survival protein kinase Akt 
and inactivates the cell death-associated protein IκB [22], suggesting multiple avenues for 
regulating cell survival. 
Interestingly, PGRMC1/25-Dx/mPR induction by TCDD is genderspecific, so that 
PGRMC1 expression is induced in male rats but repressed in females [70]. TCDD induces 
liver tumors in females but not in males [71], suggesting that gender-specific expression 
patterns may contribute to TCDD hepatocarcinogenicity. PGRMC1/25-Dx expression is 
repressed by progesterone and estrogen in murine neurons [52], and it is possible that 
these hormones repress PGRMC1 in the liver following dioxin treatment. Thus, it is 
tempting to speculate that PGRMC1 could have a signaling function in male liver tissue 
that contributes to the early stages of cancer progression. 
 
3.4.3 Chemotherapy sensitivity in human tumor cells 
Because of the role of Dap1 in damage resistance, Rohe et al. [56] tested whether 
PGRMC1 has an analogous function in cancer cells. PGRMC1 was inhibited by 
expression of a dominant-negative, heme binding deficient mutant or by siRNA, and either 
treatment sensitized breast cancer cells to the chemotherapeutic drugs doxorubicin and 
camptothecin [55]. These drugs are inhibitors of topoisomerase II and topoisomerase I, 
respectively. Peluso et al. reported similar results in ovarian cancer cells treated with 
cisplatin [58]. PGRMC1 expression is induced by chemotherapy [55, 72] and in mouse 
cells with short telomeres [73], which suffer chromosomal damage during senescence and 
crisis. Together these results suggest that PGRMC1 induction is a consequence of DNA 
damage, and PGRMC1 plays a role in suppressing damage-induced cell death in cancer 
cells. In theory, PGRMC1 could be targeted by antagonists of the PGRMC1 complex, in 
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combination with chemotherapy, to improve its tumoricidal activity, and targeting the larger 
PGRMC1 complex may have the same effect. 
 
3.5 PGRMC1 expression in the brain 
PGRMC1/25-Dx is expressed in various areas of the brain (hypothalamic area, 
circumventricular organs, ependymal cells of the lateral ventricles, meninges), particularly 
in structures involved in CSF production and in osmoregulation [74]. PGRMC1/25-Dx is 
expressed at a basal level in the cerebellum when rats are born, and the mRNA and 
protein level of PGRMC1 are increased neonatally and decreased thereafter in both male 
and female rats, without significant difference between the genders [26]. PGRMC1 is 
expressed mainly at Purkinje and external granule cells in the cerebellum of neonate rats, 
whereas in the adult cerebellum, PGRMC1 is expressed in Purkinje cells [26]. Cerebellar 
Purkinje cells are the sites of de novo synthesis of progesterone from cholesterol, where 
the steroids promote dendritic growth, synaptogenesis and spinogenesis. 
Progesterone is neuroprotective in a number of different model systems for brain lesions 
[75], and PGRMC1 is induced by progesterone after traumatic brain injury [34]. In 
addition, pseudopregnant rats have increased expression of 25-Dx [74], which also 
corresponds with neuroprotection. However, it is unclear whether PGRMC1 directly 
regulates neuroprotection and what its mechanism might be. One intriguing clue is the 
neurotrophic activity of the PGRMC1 family member neudesin, which is secreted [76]. 
Neudesin binds to heme and directly stimulates MAP kinase and Akt signaling in cultured 
neurons [76]. However, the receptor system for neudesin remains to be characterized, 
and it is unclear whether a portion of PGRMC1 might be secreted in a similar manner. 
 
3.6 Other phenotypes associated with PGRMC1 
Some phenotypes that are readily detectable in yeast have not been analyzed in detail in 
mammals. In S. cerevisiae, dap1 mutants are deficient in endocytosis [18]. The phenotype 
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was detected by measuring dye uptake, and the majority of sterol pathway mutants have 
increased dye uptake [77], probably due to membrane defects that allow the dye to leach 
into the cells. In contrast, dap1Δ mutants have decreased dye uptake, suggesting that 
Dap1 contributes to endocytosis. This phenotype suggests a role for Dap1 in membrane 
uptake and/or intracellular trafficking. Indeed, Dap1 localizes to an endosomal fraction [45] 
and contributes to the transport or storage of iron in yeast [45]. It is unclear whether this 
endocytosis phenotype is conservedin humans, but the localization of PGRMC1 to the 
endoplasmic reticulum or to punctuate cytoplasmic sites overlaps with that of the yeast 
homologue [21, 55, 58, 78]. 
In addition to regulating endocytosis, PGRMC1 has a role in regulating protein kinase-
associated signaling [22] in which PGRMC1 increases Akt activation. Akt is 
phosphorylated by the PDK1 protein kinase, and there is a putative PDK1 binding region 
on PGRMC1 [4]. The exact mechanism through which PGRMC1 activates Akt is 
unknown, but a recent work suggests a role for PGRMC1 in membrane-associated 
signaling in cancer cells [79]. The ability of PGRMC1 to activate signaling resembles that 
of yeast dap1 mutants, which have a defect in membrane-associated signaling from a G-
protein coupled receptor cascade for the yeast α-factor mating pheromone [18]. 
Interestingly, there is some indirect evidence that PGRMC1 binds to caveolin [35], which 
controls signaling through a number of receptor complexes [80-82]. Thus, one potential 
model through which PGRMC1 regulates signaling is that a PGRMC1-caveolin complex 
contributes to the secretion, stability or activation of signaling proteins at the cell 
membrane. 
Another area of research that began in model organisms involves the transcriptional 
regulation of Dap1 and PGRMC1. In S. pombe, the DAP1 gene is under the control of the 
SREBP (sterol regulatory element binding protein) homologue SRE1, particularly under 
hypoxic growth conditions [19], raising the possibility that PGRMC1 is similarly regulated 
by SREBP. Promoter mapping software predicts a sterol regulatory element in the 
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PGRMC1 promoter, but it is unclear whether this site is active. Because PGRMC1 binds 
to Insig and Scap [47], one intriguing model is that PGRMC1 could be part of a feedback 
mechanism in regulating SREBP processing. 
 
4. STRUCTURE AND FUNCTIONAL MOTIFS 
 
4.1. Cytochrome b5 domain fold 
Mifsud and Bateman recognised in 2002 that the MAPR family of which PGRMC1 is a 
member contains a cytochrome b5 domain fold [83]. In the same year, the NMR solution 
structure of the cytochrome b5-domain putative ligand binding domain of the Arabidopsis 
protein “Putative Steroid-Binding Protein” (Genbank Accession GI:40889041) was 
submitted by Suzuki and colleagues from the RIKEN Genomic Sciences Center, 
Yokohama, to the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Data Base (PDB) with PDB Accession 1J03. The structure was published in December 
2003, and appeared in the scientific literature under the name of the corresponding 
At2g24940 gene in April 2005 [84]. Another essentially identical determination of the core 
structure of the same gene product was published in 2004 by Song et al. from the 
University of Wisconsin under PDB accession 1T0G, which was determined on a slightly 
longer version of the protein [85]. This review refers to the initial 1J03 structure, which 
corresponds to the region that is highly homologous to the core mammalian cytochrome 
b5 domains of the PGRMC1 and PGRMC2 proteins. 
 
4.2. PGRMC1 is a structural homologue of Arabidopsis 1J03 
To consider potential heme-binding ligands, Min et al. [25] modelled the PGRMC1 
cytochrome b5 domain on the distantly related PDB structure 1CXY, the 
Ectothiorhodospira vacuolata cytochrome b558, which is a prokaryotic homologue of 
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cytochrome b5 [86]. Alignment of the cytochrome b5 domain of the Arabidopsis protein 
“Putative Steroid-Binding Protein” (1J03) with PGRMC1 confirms that the major structural 
elements and spacing between them are better conserved between these proteins, as 
seen in Figure 2 which shows the helices and beta strands of the cytochrome b5 domain 
according to the nomenclature of Mifsud and Bateman [83], with the exception that H-2◦ 
has been added because it was not depicted in the Mifsud and Bateman alignment, yet is 
present in the MAPR family. Many of the non-identical amino acids between 1J03 and 
PGRMC1 within the beta strands or alpha helices furthermore represent conservative 
substitutions. This demonstrates that these proteins are structurally homologous over this 
cytochrome b5 domain, and that the NMR structure of 1J03 can validly be superposed 
with the amino acid backbone of PGRMC1 and related proteins to help understand their 
structure/function relationships. Although similar theoretical structures based on the 1J03 
fold have been calculated for many of the sequences in the MODBASE data base [87], 
that is linked from SwissProt, MODBASE was not used for Figure 3. 
 
 
 
Figure 2. PGRMC1 is a structural homologue of Arabidopsis ‘putative steroid receptor’ 
(1J03). The cytochrome b5 domains of both proteins are aligned. Nomenclature for 
helices (H1–H4) and beta sheets (β1–β4) follow Mifsud and Batemen [83], with the 
exception of the helix labelled H2◦ which is present in PGRMC1 and other MAPR family 
members but absent from their nomenclature [4]. 
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4.3 ScanSite predicted motifs 
Potential protein motifs were predicted by the ScanSite “MotifScan” module function [88] 
for the PGRMC1 amino acid sequence. For a protein of just 194 amino acids (21.5 kDa), 
in addition to the cytochrome b5 domain a plurality of short motifs putatively concerned 
with protein interactions and signal transduction molecules were predicted, including two 
SH2 target sequences, an SH3 target sequence, a tyrosine kinase site, two acidophilic 
kinase sites (nominally referred to as CK2 in this review), and consensus binding sites for 
ERK1 and PDK1. Figure 3 shows the position of these predicted motifs in the PGRMC1 
sequence. In 2006 Peluso et al. also noted the presence of the predicted SH2 and SH3 
motifs using Scansite [28], as did workers from ProteoSys AG in Mainz and the University 
Women’s Hospital of Tuebingen (International Patent Application PCT/EP2006/009351, 
submitted 26 September, 2005). Note that these are not SH2 or SH3 domains, but rather 
peptide sequences that may be targeted by those domains. Notably, these motifs are all 
on the accessible surface of the folded protein (see below). In the original paper 
describing the 25-Dx clone, Selmin et al. noted that the transmembrane domain and the 
N-terminal cytoplasmic flanking region were similar to conserved sequences found in the 
cytokine/growth factor/prolactin receptor superfamily. This region, corresponding to the 
proposed SH3 target sequence, is particularly similar to an IL-6R sequence involving a 
series of prolines that is conserved in cytokine receptors where it is called box-1, which is 
necessary for the interaction with the tyrosine kinase JAK2 [13]. The truncated HC5 
protein mentioned above does not include this putative SH3 target site. Although not all of 
these sites may be biologically relevant, this, nevertheless, strongly suggests that 
PGRMC1 may be able to function as an adaptor molecule in signalling processes. 
Although only the N-terminal putative CK2 site (S56) was detected under high stringency 
Motif Scan parameters, the predicted SH2 target sequence (centred on Y179) that was 
detected under high stringency contains the predicted medium stringency C-terminal CK2 
site (S180). 
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4.4 Phosphorylation 
Both acceptor serines of the predicted CK2 sites have been detected as phosphoserine 
peptides in PGRMC1 from HeLa cell nuclear extracts [23]. Phosphoserine 180 was also 
detected in PGRMC1 from human mitotic spindle preparations 41], and from a trypsin 
digest of total mouse liver protein extract [89]. Because phosphorylated peptides are 
notoriously difficult to detect, it is possible that serine 56 was phosphorylated in all those 
samples. Working in mouse brain samples after subcellular fractionation, Munton et al. 
observed phosphorylation of murine tyrosine 180 only from synaptosomal and not from 
synaptic vesicle or post-synaptic density preparations. This amino acid is homologous to 
the human Y179 tyrosine phosphate acceptor of the predicted C-terminal SH2 target 
sequence, suggesting that PGRMC1 may be relocalised by tyrosine phosphorylation. This 
result was notable in this context because PGRMC1 was almost 15-fold more abundant in 
the post-synaptic density fraction where no phosphorylated species were detected [37]. 
Selmin et al. [70] also noted the presence of slightly higher molecular weight species of 
PGRMC1 in MCF7 breast cancer cell line which they speculated may have represented 
differentially phosphorylated forms induced by 10nM dioxin treatment. They concluded: 
“Our results indicate that the mPR protein (PGRMC1) may exist in different states of 
phosphorylation, which would cause changes in the apparent MW. This latter explanation 
would be in line with the fact that RT-PCR experiments always detect one single 
transcript, and previous Northern assays which showed a single mPR RNA size, 
corresponding to a protein of ≈25 kDa”.  
 
4.5 ITAM motifs and vesicular trafficking 
Runko and Kaprielian [17] noticed the presence of several conserved YXX(Ф) consensus 
motifs (where represents an aliphatic amino acid) in PGRMC1 and related proteins from 
several organisms. These tyrosine-based motifs are thought to be involved in vesicle 
transport, and particularly so when they occur in a so-called tight turn on the protein 
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surface, in the endocytic internalisation of proteins from the cell surface at clathrin-coated 
pits that contain caveolin [90]. YXX(Ф) motifs are also known in the literature as 
immunoreceptor tyrosine-based activation motifs (ITAMs), which are characterized by 
canonical YXX(L/I/V) sequences [91-94]. The observed colocalisation of PGRMC1 (called 
NGPR by those authors) with caveolin and the effects of digitonin treatment on ligand 
binding [35, 95] are consistent for such a proposed role in endocytic processes and 
membrane trafficking, although this remains undemonstrated. 
 
4.6 Structural model 
A model for PGRMC1 is shown as Figure 3, based upon homology to Arabidopsis 1J03 
(Figure 2), and showing the structural motif labeling nomenclature discussed. Using the 
aligned domain topology of these two protein structures, note that the N-terminal and C-
terminal regions of the cytochrome b5 domain would be on the same side of the structure, 
which would be the opposite side of the protein to the ligand-binding pocket. Therefore the 
predicted PGRMC1 N-terminal SH3 target recognition site and CK2 site centred on 
residues P62 and S62, are most probably adjacent and functionally overlapping to one 
another on the surface of the related PGRMC1 protein directed away from the ligand 
binding pocket. Similarly, the predicted SH2 domain and CK2 site centred on Y179 and 
S180, respectively, are also probably located on the same surface on the opposite side of 
the protein from the ligand-binding site. This suggests that ligand-binding of PGRMC1 
could occur simultaneously with protein interactions through these sites. It is worthwhile to 
recall that ligand-binding to nuclear hormone receptors induces large structural alterations 
in those proteins, to the extent that the ligands are often totally shielded from aqueous 
solution by the protein ligand-binding pockets [96]. So it is easily conceivable that ligand-
binding could affect the conformations and specificities of any putative protein interaction 
motifs in PGRMC1. 
The predicted Shc consensus-like SH2 target sequence as evolutionarily inserted as a 
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loop between conserved cytochrome b5 domain helices 3 and 4 (‘H3-H4 SH2’ in Figure 3) 
in the MAPR family that is absent in the ancestral cytochrome b5 domain fold. In the 
crystal structure of bovine cytochrome b5, these two helices are joined by a short linker of 
just a few amino acids at the rim of the ligand-binding pocket. In the plant 1J03 structure 
the amino acids between helices 3 and 4, which exhibit marked amino acid homology to 
the predicted SH2 target motif of PGRMC1, fold in the direction away from the ligand 
pocket leaving the ligand-binding region accessible. If these amino acids do function as 
the target for an SH2 domain in vertebrates, we are faced with an extremely interesting 
situation. The SH2 domain is thought to have evolved along with multicellularity in 
eukaryotes, and examples have been identified on the basis of consensus SH2 signatures 
in plants [97]. The vertebrate PGRMC1 and PGRMC2 exhibit absolute conservation of the 
putative Y138 phosphate acceptor amino acid of PGRMC1 [17]. The plant protein 1J03 
also exhibits strong homology across this region, with several amino acids in the putative 
SH2 target loop exhibiting absolute conservation, and several others having undergone 
conservative substitutions. However the position homologous to Y138 of PGRMC1 is 
occupied by a serine (also a phosphate-accepting amino acid) in the plant protein (see 
Figure 2), which merits the initiation of experiments aimed at functional classification of 
this stretch of amino acids in plants and mammals if the SH2 target sequence status is 
verified. 
Interestingly, structural alignment of PGRMC1 with the plant protein also revealed that 
P108 at the centre of the putative ERK1 binding site was exposed at the surface of the 
protein immediately N-terminal to helix 2◦ (Figure 3), while T160 at the centre of the 
putative PDK1 kinase binding site was also exposed on the surface of helix 4. In fact, the 
P108-centred putative ERK1 binding site is situated on the lip of the binding pocket 
adjacent to the position where a cytochrome b5 histidine interacts with the heme ligand, 
and this proline is conserved in related proteins from yeast to mammals [83]. Therefore 
the putative ERK1 binding site could conceivably be inhibited by recruitment of the ligand 
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to the binding pocket, or vice versa. Similarly, the predicted phosphorylation of Y112 by 
Abl or Lck kinase could also potentially influence ligand binding. However in the absence 
of experimental analyses, these alluring speculations remain rather circumspect. 
Notably, several of the YXX (Ф)/ITAM potential motifs described by Runko and Kaprielian 
(particularly Y165 and perhaps Y112: Figure 3) are actually accessible at the protein 
surface on sharp turns following a helix in the modeled PGRMC1 structure, which is the 
structural prerequisite for involvement of ITAMs in vesicle trafficking [90]. Y42 immediately 
follows the transmembrane helical domain, and could also be involved in a sharp 
backbone turn. This situation is highly unlikely to have arisen by chance, and supports the 
prediction of Runko and Kaprielian that PGRMC1 is involved in membrane trafficking. The 
functional relevance of these putative structural motifs certainly merits further scrutiny. 
 
4.7 Functional model 
These combined observations lead to a proposed model for the cellular function of 
PGRMC1. As stated above, the preponderance of protein motifs putatively associated 
with signal transduction in the predicted 21.5 kDa protein is highly suggestive that the 
protein indeed functions as a signalling adaptor molecule involved in membrane 
trafficking, and that the activity may be kinase- and/or ligand-regulated. Strikingly, the 
spatial juxtaposition of the SH2 and SH3 target motifs in Figure 3 would induce intimate 
local concentration of putative interacting proteins relative to each other, such as possibly 
kinases and their substrates, or proteins located on different sub-cellular membranes, 
potentially greatly facilitating biological activities. This provides a highly plausible scenario 
for the mode of action of PGRMC1. The protein is schematically represented in Figure 4 
as a ligand-binding signalling adaptor protein. In the CK2-phosphorylated state of this 
hypothetical model, one or more of the N-terminal SH3 target motif and C-terminal SH2 
target motif are phosphorylated by an acidophilic kinase such as CK2, and do not interact 
with other proteins. Since the C-terminal CK2 site is more highly evolutionarily conserved, 
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and overlaps exactly with the corresponding predicted SH2 target, it is the more likely of 
these motifs to be functionally regulated by CK2. However in the non-CK2-phosphorylated 
state the CK2 site/s is/are dephosphorylated in the model, possibly leading to relocation of 
PGRMC1 to specific subcellular compartments as perhaps observed in various literature 
reports. This would entail accompanying tyrosine phosphorylation if an SH2 target 
sequence was involved. The predicted SH2 target between helices 3 and 4 of the 
cytochrome b5 domain may interact with other proteins. It is tempting to speculate that 
interactions through these putative motifs are regulated by ligand-binding, tyrosine 
phosphorylation of the putative Abl/Lcklike site at Y112, and/or binding of either ERK1 
and/or PDK1 to their respective predicted sites on the edge of the ligand pocket. 
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Figure 3. PGRMC1 modelled using the Arabidopsis 1J03 NMR structure. (A) The amino 
acid sequence of PGRMC1 (SwissProt O00264), showing predicted functional motifs from 
Table 1 below the sequence. The cytochrome b5 domain is indicated above the 
sequence, with the positions of helices and beta sheets after Mifsud and Bateman [83] 
and Figure 2. The position of tyrosines of the putative ITAM/YXX(Ф) motifs according to 
Runko Kaprielian [17] are shown in pink boxes above the amino acid sequence. (B and C) 
The structure of PGRMC1 as modelled with the Arabidopsis 1J03 coordinates (which 
were depicted with RasMol), showing the positions of the colour-coded features from (A). 
(B) View from the side of the ligand binding pocket. (C) View from the side opposite to that 
containing the ligand-binding pocket. The positions of PGRMC1 features, which are not 
present in the 1J03 structure, are schematically portrayed by circles, which are colour-
coded to correspond with (A). H2 was not shaded red as a helix by the RasMol software, 
although the helical arrangement of the peptide backbone is obvious [4]. 
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Figure 4. Hypothetical model for PGRMC1 function as a ligand-binding adaptor molecule. 
(A) Schematic model of PGRMC1, based upon the model structure of Figure 3. (B) 
According to the hypothetical model, when PGRMC1 is phosphorylated by CK2 at S56 
and S180 the putative SH3 and SH2 target sequences are unavailable to interact with 
SH3- and SH2-domain-containing proteins. (C) In the absence of S56 and/or S180 
phosphorylation of these interaction motifs PGRMC1 possibly forms a functional protein 
complex. (D) Cholesterol and/or steroid binding may require dimerisation of PGRMC1 
from a ‘28 kDa’ monomer to a ‘56 kDa’ dimer. It is conceivable that the subunits bind to 
membranes on different subcellular organelles. (E) Protease action, such as by the S1P 
or S2P proteases which cleave the cholesterol sensitive SREBP [98], may release a ‘56 
kDa’ dimer to the cytoplasm, where it can bind heme. These speculative scenarios are 
intended to be mechanistically illustrative, and neither mutually exclusive nor functionally 
comprehensive. Translocation(s) between sub-cellular locations may be involved in 
change between putative functional scenarios (arrows) [4]. 
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5. POSSIBLE DISEASE RELEVANCE 
 
PGRMC1 was cloned as 25-DX as a dioxin-inducible gene, which suggests a possible 
function in stress-alleviation or stress response, an interpretation which seems to be 
supported by subsequent data. Progesterone has a neuroprotective effect. We have 
already seen that progesterone treatment of spinal chord-injured rats led to increased 
PGRMC1 expression in the rat spinal cord [34], and PGRMC1 is also expressed in brain 
regions involved in water homeostasis, where it is up-regulated after traumatic brain injury 
[74]. Although there is still no evidence of direct steroid binding to PGRMC1, as reviewed 
above, there is reasonable evidence for a role in steroid binding in complex with other 
proteins, and for influencing steroid synthesis via the cholesterol regulatory system, and/or 
metabolism. Another potential avenue of disease relevance lies in the immune system. 
PGRMC1 has been identified in intraepithelial CD8-positive and estrogen receptor beta-
positive T lymphocytes from human oviduct epithelium, where a role in the hormonal 
responsiveness of that tissue was suggested [99]. However no diseases associated with 
PGRMC1 have yet been reported in these systems. 
In a recent review, Kampa and Castanas argue that membrane steroid receptors may 
constitute major future targets for therapy in neoplastic cells [100], and the strongest 
indication of a disease-related function for PGRMC1 so far is in cancer. Nie et al., from 
Johnson and Johnson Pharmaceuticals, identified PGRMC1 in a 2006 toxicogenomics 
report as one of six genes whose expression profiles could predict the action of 
nongenotoxic carcinogens with over 80% accuracy. Yet typically for this protein, they were 
unable to classify PGRMC1 into one of the functional networks predicted by an Ingenuity 
Systems Pathways Knowledge Base because PGRMC1 was not functionally annotated in 
that database [66]. This further highlights the enigmatic level at which the biology of 
PGRMC1 is presently understood against a backdrop suggesting that its role is, 
nevertheless, probably quite important. 
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PGRMC1 is more abundant in several tumours and/or tumour cell lines than in control 
healthy tissues. In 2003 Difilippantonio and colleagues from the Charit´e Hospital in Berlin 
and the National Cancer Institute in Bethesda, Maryland, found by subtractive 
hybridisation cloning that PGRMC1 was consistently about 2–4 fold more abundant in cell 
lines from lung cancers than from healthy lung cell lines, however PGRMC1 was only one 
of multiple identified genes, and the finding was not extended to primary clinical tissues 
[59]. In 2005 Crudden et al., from the Craven and Mannheim groups, showed by Western 
blot that PGRMC1 is more abundant in breast cancer than in healthy tissue and it is 
variously overexpressed in some colon and thyroid tumours [57]. The same year, Craven 
and coauthors further proposed that PGRMC1 belonged to a group of genes that regulate 
susceptibility of cancer cells to chemotherapy [72]. Kurek, Clare, Neubauer, and 
colleagues from the University Women’s Hospital of Tuebingen and ProteoSys AG in 
Mainz identified three isoforms of PGRMC1 in breast cancer tumors by 2D-PAGE, two of 
which were differentially more abundant in tumours lacking the estrogen receptor (ER), a 
phenotype which correlates with both an activated wound response and negative clinical 
outcome. Immune histochemistry studies suggested a more micro-heterogenous 
subcellular distribution than the diffuse cytoplasmic staining observed in tumors that were 
ER-positive (international patent applications WO2006029836, submitted 14th September 
2004; PCT/EP2006/009351, submitted 26 September 2005). 
It has been proposed that PGRMC1 centrally regulates susceptibility to chemotherapy by 
heme-binding [55], although we have already noted that no involvement of a cytochrome 
P450 interaction or accessory redox function has yet been demonstrated. Peluso, 
Wehling, Losel and colleagues [28, 101] argue that the protein complex of PGRMC1 and 
PAIRBP1 induces the anti-apoptotic effect of progesterone on granulosa cells, an effect 
which could also be relevant for cancer and other pathogenic cells. 
However it is possible that PGRMC1 exerts functions as an adapter protein independently 
of its ligand-binding, or perhaps regardless of the bound ligand. In addition to PAIRBP1, 
 32 
we have seen that PGRMC1 is implicated in the UNC-40/DCC receptor for Notch on the 
surface of migrating neurons, in a signalling system which does not harbor an obvious or 
reported requirement for ligand binding. In C. elegans, the UNC-6/Netrin response is 
associated with presence of two receptors: UNC-40/DCC and UNC-5. These belong to the 
class of dependence receptors which induce one of two responses, such as survival or 
apoptosis, in the presence or absence of ligand. It has emerged that the Netrin, UNC-
40/DCC, UNC-5 pathway is crucially important in mammalian tumorigenesis. In the 
absence of Netrin its receptors induce p53-dependent apoptosis, and the Netrin gene is 
transcriptionally regulated by p53. Hence the UNC-5 family and UNC-40/DCC receptors 
have been identified as tumor-suppressors whose deletion can lead to cancer, which 
explains why Netrin is a survival factor [102-105]. Therefore any ability of PGRMC1 to 
interact with DCC and influence its pro-apoptotic activity in the absence of Netrin could be 
of paramount importance for tumour cells. It is unknown whether these molecules are 
involved in the apparent upregulation of PGRMC1 after tissue injury that was observed by 
Velardo et al. from the University of Florida [106], who performed systematic gene 
expression profiling in a model based upon physically induced mouse spinal chord injury. 
Those authors identified waves of co-regulated genes that were temporally induced after 
tissue damage. PGRMC1 mRNA was up-regulated relatively late (many days to weeks 
after damage) along with a cluster of genes involved in tissue repair. 
In relation to cholesterol regulation, it was mentioned above that HMG-CoAR is 
transcriptionally activated by SREBPs after they are escorted from the endoplasmic 
reticulum to the Golgi by the PGRMC1-interacting protein SCAP, thereby activating 
cholesterol synthesis under conditions of low cholesterol. This could conceivably 
contribute substantially to neoplastic status. Signalling requires the presence of proteins 
accumulated in cholesterol-enriched, detergent-insoluble and caveolin-associated 
microdomains which have come to be called lipid rafts [107]. In fact it has been 
demonstrated that cellular cholesterol levels determine the properties of rafts, and thereby 
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regulate the biological response of cells [108, 109]. However any putative 
neoplasminfluencing effects of PGRMC1 need not necessarily involve cholesterol or rafts. 
HMG-CoAR catalyses the reduction of acetyl CoA to l-mevalonate, which is the precursor 
for the so-called mevalonate pathway, which leads not only to the synthesis of the carbon-
skeleton of cholesterol and steroids, but also to the synthesis of isoprenoids that are 
necessary for the prenylation and attendant membrane localisation of proteins involved in 
signal transduction such as the G-protein RhoA. The mevalonate pathway has therefore 
emerged as one of the recently most investigated systems for anti-cancer treatment, 
particularly involving statins, which inhibit HMGCoAR activity [110-112]. 
 
6. PGRMC1 AND REPRODUCTION 
Recently PGRMC1 has been demonstrated in female reproductive tissues of different 
mammalian species, suggesting a role for it in reproduction. 
6.1. Uterus and pregnancy 
Chen et al. [113] compared the protein profiles differentially expressed in the human 
endometrium between the proliferative and secretory phases of normal menstrual cycles 
by 2D differential in-gel electrophoresis. Mass spectrometry identified 76 proteins 
representing 41 different gene products and immunohistochemistry confirmed the 
observed changes in 3 representative proteins (Rho-GDIalpha, CLIC1, PGRMC1). 
PGRMC1 was more highly produced in the proliferative than the secretory phase and 
immunostaining studies revealed that it was confined to the stromal component of 
proliferative phase endometrium. Importantly PGRMC1 expression was observed 
predominately during the midproliferative phase when circulating progesterone levels are 
very low, suggesting that progesterone may not be its biologically relevant ligand. Given 
that progesterone resistance and dysregulation across the endometrial cycle is an 
 34 
important feature of endometriosis and infertility [114] it may be that PGRMC1 
dysregulation contributes to these disorders.  
These findings were confirmed in uterine tissues in mice [115] where endometrial 
expression of PGRMC1 was up-regulated in the stromal compartment from estrus to 
metestrus and reduced during diestrus. PGRMC1 expression was studied also during 
early gestation. Immunohistochemical analyses demonstrated that PGRMC1 was either 
diffusely expressed throughout stromal cells cytoplasm or highly abundant in the nucleus. 
The protein continued to show dynamic localization during the decidualization process. 
Stromal cells at the outer margins of the secondary decidualization zone showed only 
nuclear expression of PGRMC1, while stromal cells having undergone terminal 
differentiation expressed PGRMC1 throughout the cytoplasm. PGRMC1 was also 
detected in the myometrium during pregnancy and was found dually expressed in 
decidualized stromal cells at both the antimesometrial and mesometrial poles of the 
implantation site. Interestingly, PGRMC1 was expressed in the microvasculature at the 
mesometrial aspect of the implantation site. These findings suggest that PGRMC1 
promotes differentiation, since the protein expression increases in endometrial cells 
undergoing steroid-depended terminal [39]. In addition, the same report described 
PGRMC1 in the human placenta and associated membranes with the most abundant 
expression in smooth muscle of the placental vasculature, villous capillaries and the 
syncytiotrophoblast suggesting the hypothesis that this protein functions in events 
important in early pregnancy including cellular differentiation, modulation of apoptosis and 
steroidogenesis [116, 117].  
The expression of PGRMC1 has been described also in early equine conceptuses [118]. 
Horse conceptuses recovered on days 7, 10 and 14 after ovulation were examined for 
PGRMC1 mRNA expression using quantitative rtPCR. mRNA for PGRMC1 was detected 
at all stages examined and PGRMC1 expression increased during the day 7-14 period. 
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The study demonstrates that equine conceptuses express PGRMC1 during the period 
encompassing rapid conceptus growth, differentiation and maternal pregnancy 
recognition. 
 
6.2. Ovary and oocyte 
Other reports investigated the localization and function of PGRMC1 in the ovary. In 
particular immunohistochemical studies, performed in rat, localized PGRMC1 in ovarian 
germinal epithelium cells, granulosa, theca and luteal cells [28] and verified that PGRMC1 
expression in granulosa and luteal cells was developmentally regulated [28]. In preantral 
and antral follicles before eCG treatment in fact, PGRMC1 was detected in a limited 
number of granulosa cells, apparently localized to the nuclei of many PGRMC1-
expressing granulosa cells. In a few granulosa cells before eCG treatment, PGRMC1 
appeared to be concentrated at or near the plasma membrane, with its expression 
restricted to a limited section of the plasma membrane. After eCG treatment the 
localization dramatically changed such that PGRMC1 expression was almost exclusively 
at or near select regions of the plasma membrane. With hCG induction of ovulation and 
luteinization, PGRMC1 expression increased. Unlike granulosa cells, 100% of the luteal 
cells expressed high levels of PGRMC1, with PGRMC1 being distributed throughout the 
cell. 
Lately, the same authors proved that PGRMC1 regulates granulosa cell viability verifying 
its role as mediator of Progesterone’s antiapoptotic action [78, 119]. In an attempt to 
identify some of the genes whose expression might be part of the putative genomic action 
of PGRMC1, mRNA levels of numerous genes involved in apoptosis were assessed using 
real-time PCR microarrays. Treatment with PGRMC1 siRNA in the absence of P4 
significantly altered that pattern of gene expression compared to treatment with scrambled 
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(control) siRNA. The overall effect was to increase the mRNA levels of many genes that 
are involved in promoting apoptosis. This suggests that PGRMC1, which is not bound to 
P4, regulates gene expression in a manner that would make the cells more susceptible to 
undergoing apoptosis. This finding fits well with PGRMC1's cell survival function [4, 120] 
and is consistent with the observations that depletion of PGRMC1 makes ovarian [58, 78], 
endometrial [121] and breast cancer [55, 121] cells more sensitive to the apoptotic effects 
of various chemotherapeutic agents. 
Expression of PGRMC1 mRNA was found in granulosa or luteal cells in humans [101], 
mice [122], pigs [123] and cows [124]. 
Fertility in mammals is dependant on females having an adequate primordial follicle pool 
to supply oocytes for fertilization and its number is one determinant of the reproductive 
lifespan [125]. Primordial follicle assembly occurs during fetal development before birth 
[126]. Microarray analysis and RT-PCR indicated that PGRMC1 is continuously and highly 
expressed throughout all the development of bovine fetal ovary [127]. This result raises 
the possibility that PGRMC1 may support the primordial follicle assembly. 
PGRMC1 is also expressed in bovine, rat [28] and human oocytes [128]. Recently 
PGRMC1 was detected among the proteins of the mitotic spindle [129], suggesting a role 
for it in mitosis. Moreover, the mRNA that encodes PGRMC1 is present in bovine oocytes 
at a very high level similar to that of actin [130]. In spite of its high level of expression, little 
is known about PGRMC1 and oocyte function. Since PGRMC1 is present in mitotic 
spindle [24, 129], it could be directly involved in regulating oocyte maturation (meiosis). 
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7. AIM OF THE STUDY 
Because of the possible relevance in reproductive function, the present study was 
undertaken in order to characterize the role of PGRMC1 in bovine infertility. In particular 
the study has been developed in three parts. In the first part the expression and the 
localization of PGRMC1 in the bovine reproductive system during the different phase of 
the estrous cycle were evaluated. In the second part the role of PGRMC1 in oocyte 
function and specifically in the control of meiotic division and its partecipation in the 
process of chromosomal congression was analyzed. In the third part of the study we 
assessed the specific role of PGRMC1 in the decreased developmental capability of 
oocytes from dairy cows of reproductive age with a reduced ovarian reserve, as a 
proposed model of premature ovarian failure. 
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8. Part I 
 
Expression of Progesterone Receptor Membrane Component-1 in bovine 
reproductive system during estrous cycle 
 
SUMMARY 
Several reports suggest the participation of progesterone receptor membrane component 
1 (PGRMC1) in progesterone signaling in the reproductive system. This study aimed to 
investigate the presence and localization of PGRMC1 in bovine ovary, oviduct and uterus, 
during the follicular and luteal phases of the estrous cycle. 
In the ovary, PGRMC1 has been detected in surface germinal epithelium, granulosa cells, 
theca cells and in the germinal vesicle of the oocytes at all stages of folliculogenesis. In 
the corpus luteum the expression of PGRMC1 was influenced by the stage of the estrous 
cycle. In the oviducts and in the uterus horns, PGRMC1 was immunolocalized in the 
luminal epithelium, in the muscle layer cells and in the endothelial cells. In the uterus, 
PGRMC1 was intensely localized also in the glandular endometrium. However, in the 
oviducts and in the uterus horns, the localization of PGRMC1 was independent of the 
stage of the estrous cycle and of whether evaluating the ipsilateral or the contralateral 
organ. 
 In conclusion, the present immunohistochemical study showed that PGRMC1 is 
located in various compartments of the bovine female reproductive organs and, with the 
exception of the corpora lutea, PGRMC1 localization showed similar pattern during 
different stage of the estrus cycle. 
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INTRODUCTION 
 Progesterone receptor membrane component 1 (PGRMC1) belongs to the 
membrane-associated progesterone receptor (MAPR) proteins family that is widespread 
in eukaryotes and involved in regulating numerous biological functions [4]. PGRMC1 is 
predominantly located in intracellular membranes and colocalizes with the endoplasmic 
reticulum and Golgi apparatus in rat liver cells and hippocampal Pukinje cells [21, 26]. 
Several studies described a nuclear or chromosomal localization. PGRMC1 was detected 
in nuclear extracts of HeLa cells [23], among the protein of the human mitotic spindles [24, 
129], and recently has been proposed in regulating microtubule stability in human and rat 
ovarian cell mitosis [5]. Various ovarian cell types including granulosa cells and ovarian 
surface epithelial cells as well as ovarian tumors express PGRMC1 where it plays an 
essential role in promoting the survival of both normal and cancerous ovarian cell in vitro 
[131]. 
 Recently PGRMC1 expression has been demonstrated in several female 
reproductive tissues in different mammalian species. PGRMC1 has been detected in 
uterine and placental tissues of the mouse and human [115] and it is among the proteins 
that were differentially expressed in the human endometrium during menstrual cycle [113].  
Other reports investigated the localization and function of PGRMC1 in the ovary. In 
particular immunohistochemical studies localized PGRMC1 in granulosa cells, theca cells 
and ovarian surface epithelial cells (germinal epithelium) in rat [28]. Moreover the 
expression of PGRMC1 mRNA was found in granulosa or luteal cells in humans [101], 
mice [122], pigs [123] and cows [124]. Several works suggest that progesterone mediates 
its antiapoptotic action through PGRMC1 [78, 119]. 
 PGRMC1 is also expressed in bovine [132], rat [28] and human oocytes [128]. 
Recently, PGRMC1 was associated to the meiotic spindle suggesting a role in oocyte 
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maturation, which may be specifically related to the mechanism by which chromosomes 
segregate [132]. However, with regard to localization of the protein, a recent work did not 
detect PGRMC1 in the bovine oocyte [133]. 
To date there is little information on the localization of PGRMC1 in the reproductive 
organs of the cow. Thus, the aim of the present study was to examine the presence and 
localization of PGRMC1 in a variety of cow reproductive organs, including ovary, oviduct 
and uterus during the follicular and luteal phases of the estrous cycle using 
immunohistochemistry. 
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MATERIAL AND METHODS 
Tissue collection 
All the chemicals used in this study were purchased from Sigma Chemical 
Company except for those specifically mentioned. Bovine ovary, oviduct and uterus were 
recovered at a local abattoir (INALCA JBS S.p.A., Ospedaletto Lodigiano, LO, IT 2270M 
CE, Italy) from non-pregnant dairy cows, 4 to 8 yrs old, subjected to routine veterinary 
inspection and in accordance to the specific health requirements stated in Council 
Directive 89/556/ECC and subsequent modifications, and were transported to the 
laboratory on ice. The stage of the estrous cycle was assessed by morphological 
observations of the ovary [134]. In particular, animals in which one of the two ovaries 
presented an active corpus luteum were classified as belonging to luteal phases of 
estrous cycle while animals in which one of the two ovaries presented the ovulatory follicle 
and a regressed corpus luteum were classified as belonging to follicular phases of estrous 
cycle [135, 136]. 
 For each animal, both ovaries were transversely cut and 2-4 fragments of corpus 
luteum and 2-4 fragments of ovarian cortex were collected; from both oviducts samples of 
isthmus, ampulla and infundibulum were separated. Finally the apical third of each uterine 
horns were isolated dissecting at about 5 cm from the uterus-isthmic junction [137]. All 
samples were fixed in B5 (Formalin-Mercury II Chloride) fixative (Bio-Optica, Milan, Italy) 
for 12-24 hours, dehydrated by a graded series of ethanol, cleared with xylene, paraffin 
embedded and sectioned at 5 µm on glass slides, previously treated with Vectabond 
(Vector Laboratories, Burlingame, CA, USA) to enhance the adherence of tissue. 
 
Western blot analysis 
Western blot analysis was performed as previously described with minor 
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modifications [132]. Briefly, aliquots of 50 mg of ovarian cortex and corpus luteum were 
homogenized in RIPA buffer, which was supplemented with complete protease and 
phosphatase inhibitor cocktails, incubated for 30 minutes on ice and then centrifuged at 
14000 g for 20 min at 4°C. Total amount of protein was determined using the Bio-Rad 
Protein Assay (Biorad) and 20 µg of total protein was used for western blot analysis. 
Equal protein loading was verified by Ponceau staining. PGRMC1 immunodetection was 
conducted using different concentrations (1 µg/ml and 0.3 µg/ml) of a rabbit polyclonal 
antibody (Sigma Prestige, Cat. No. HPA002877) or a goat polyclonal antibody (AbCam, 
Cat. No. ab48012) over night at 4°C. PGRMC1 was revealed using an anti-rabbit or anti-
goat HRP-labelled antibodies (1:8000) and SuperSignal® West Pico Chemiluminescence 
Substrate (PIERCE Biotechnologies Inc, Rockford, IL, USA). Negative controls were 
conducted by omitting the primary antibodies.  
 
Immunohistochemistry 
 Indirect immunohistochemistry was carried out to evaluate the expression and 
localization of PGRMC1. Endogenous peroxidase activity was eliminated by incubation 
with 3% (v/v) H2O2 in methanol for 30 minutes. Then sections were incubated with 10% 
(v/v) normal goat serum or normal rabbit serum, 0.3% (v/v) Triton X-100 and 3% (w/v) 
bovine serum albumin (BSA) in phosphate buffered saline (PBS) for 30 minutes to block 
non-specific binding of secondary antibody. In a preliminary study the sections were 
incubated overnight at 4°C with different concentrations (0.96, 0.48, 0.24 or 0.16 µg/ml) of 
polyclonal rabbit anti-PGRMC1 (Sigma Prestige) or polyclonal goat anti-PGRMC1 
(Abcam) diluted in PBS with 1% (w/v) BSA and 0.3% (v/v) Triton X-100. In all the 
subsequent experiments the rabbit polyclonal antibody was used at a concentration of 
0.48 µg/ml. Primary antibodies were detected by using a biotinylated anti-rabbit or anti 
goat IgG (Vector Laboratories), diluted 1:400 in PBS with 1% (w/v) of BSA and detected 
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with the Vectastain Elite ABC kit (Vectastain Elite ABC kit, Vector Laboratories). For color 
development, all sections were incubated with DAB substrate (DAB substrate kit for 
peroxidase, Vector Laboratories) for 2 minutes. After staining, the samples were 
counterstained with hematoxylin QS (Vector Laboratories). Negative controls were 
performed by omitting the primary antibodies. Samples were analyzed on a Nikon Eclipse 
microscope (Nikon Corp., Tokyo, Japan) in bright field at a magnification of 200X-400X. 
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RESULTS 
 Preliminary studies were conducted in order to compare the specificity and the 
sensitivity of two antibodies (polyclonal rabbit anti-PGRMC1 and polyclonal goat anti-
PGRMC1) by western blot and immunohistochemical analysis with different primary 
antibodies concentrations. 
 Western blot analysis confirmed that PGRMC1 was specifically detected in ovarian 
cortex as a ≈ 26 kDa protein (Figure 5A). However, only the polyclonal rabbit anti-
PGRMC1 detected the protein, while under the same experimental conditions the goat 
polyclonal antibody did not. Conversely, the goat polyclonal antibody only detected the 26 
kDa protein when higher amounts of total proteins (100 and 50 µg) were loaded on the gel 
(Figure 5B). Moreover, antibody titration on immunohistochemistry showed a higher 
sensitivity of the polyclonal rabbit anti-PGRMC1 since this antibody detected PGRMC1 in 
the granulosa cells, in the theca layer and in the endothelial cells of blood vessels at all 
concentration tested, whereas the goat polyclonal antibody detected a much weaker 
signal at the corresponding concentration (Figure 6A and 6B lower panel). In addition the 
rabbit polyclonal detected a much higher PGRMC1 signal in cumulus cells and germinal 
vesicle of the oocyte when compared with the goat polyclonal used at the same 
concentration (Figure 6B upper panel). Therefore, the polyclonal rabbit anti-PGRMC1 
antibody, at a concentration of 0.48 µg/ml was utilized in further experiments to assess 
PGRMC1 localization in bovine ovary, oviduct and uterine horn.  
 A total of 8 animals (4 for each estrous cycle) were analyzed for PGRMC1 
localization. Data are and shown in Figures 7, 8 and 9 and summarized in Table 1. 
In all experiments, negative controls were conducted in the absence of the primary 
antibody and did not show any staining.  
 In the ovary, immunohistochemical studies showed that PGRMC1 was expressed 
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in the follicles during all the stages of folliculogenesis, in the oocyte and in its surrounding 
cumulus cells, both in the nucleus and inside the cytoplasm (Figure 7). Oocyte showed a 
positive staining in the germinal vesicle (GV), while the ooplasm displayed only a weak 
signal (Figure 7, A and B). In the cumulus oophorus, granulosa cells lying closer to the 
oocyte exhibited a more intense signal than granulosa cells in the outer layers (Figure 6 B, 
up left). PGRMC1 was also detected in theca layers (Figure 7 C). Furthermore, PGRMC1 
was immunolocalized in the germinal epithelium of the ovarian surface (Figure 7 D) and in 
the endothelial cells of the stromal vessels (arrows in Figure 7 A, B and C). On the 
contrary, in ovarian stromal tissue cells PGRMC1 was weakly detected. 
Immunolocalization of PGRMC1 revealed a similar expression pattern for the follicular and 
luteal phase of the estrous cycle and differences were not observed between the two 
ovaries of the same animal. 
 In contrast, in the corpus luteum PGRMC1 was differently immunolocalized 
depending on the stage of the estrous cycle (Figure 8). During the luteal phase (Figure 8 
A) most of the luteal cells showed a cytoplasmatic staining for PGRMC1, with signal 
intensity varying from intense to weak, while the signal was completely absent only in a 
few cells. During the follicular phase (Figure 8 B) PGRMC1 was detected as a weak signal 
in the cytoplasm of most of the cells. In both phases PGRMC1 was expressed in the 
endothelial cells and was detected as an intense to weak signal in the nuclei of the luteal 
cells.  
 Microscopic examination of PGRMC1 localization in the oviduct revealed a specific 
nuclear and cytoplasmic staining for PGRMC1 in the luminal epithelium (Figure 9 A and 
B), in the muscle layers (Figure 9 C) as well as in the endothelial cells. On the contrary 
PGRMC1 was weakly expressed in the cells of lamina propria and submucosa (stromal 
cells). No differences were observed between infundibulum (Figure 9 A), ampulla (Figure 
9 B), and isthmus (Figure 9 C), neither in follicular nor luteal phase, either between the 
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two organs of the same animal. 
 In the uterus, PGRMC1 was observed as an intense signal in the luminal 
epithelium (Figure 9 E), glandular endometrium (Figure 9 F), as well in the muscle layers 
(Figure 9 F) and in the vessels while a weak signal was present in the stromal 
compartment. As in the oviduct, a positive staining was present both in the nucleus and in 
the cytoplasm of all the cells and any difference was observed between the estrous 
stages and between the two horns. 
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Table 1. Immunohistochemical localization of PGRMC1 in the reproductive tracts during 
estrus cycle. PGRMC1 is indicated as intense (+) weak (±) or negative signal in the 
different organs. 
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Figure 5. Detection of PGRMC1 in bovine ovarian cortex and corpus luteum by 
western blot analysis 
A) Western blot analysis showing PGRMC1 expression in bovine ovarian cortex and 
corpus luteum (20µg total protein/lane) using the rabbit polyclonal (Sigma-Prestige) or the 
goat polyclonal (Abcam) antibodies at different concentrations. Note that only the rabbit 
polyclonal anti-PGRMC1 antibody detected the protein, while under the same 
experimental conditions the goat polyclonal antibody did not. B) Western blot analysis of 
PGRMC1 expression in ovarian cortex with the goat polyclonal antibody using increasing 
amount of total protein (50 and 100µg). 
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Figure 6A (legend on next page) 
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Figure 6B. Titrations of different primary antibodies to detect PGRMC1. 
A: Representative images of PGRMC1 localization in a medium antral follicle wall using 
rabbit polyclonal (Sigma-Prestige) and goat polyclonal (Abcam) primary antibodies. The 
values on the left refer to the concentrations (µg/ml) of the primary antibodies used. Note 
that rabbit polyclonal antibody shows a specific staining for PGRMC1 in the granulosa 
cells, in the theca layer and in the endothelial cells of blood vessels at all concentration 
used, whereas a weaker signal was detected by the goat polyclonal antibody under the 
same experimental conditions. No immunoreactivity was seen in negative controls where 
incubation with the primary antibodies was omitted. Final magnification = 200X, scale bar 
= 50 µm. 
B: Representative images showing details of PGRMC1 localization in oocytes and 
medium antral follicle wall using the two antibodies under the same experimental 
conditions at a concentration of 0.48 µg/ml. Note that rabbit polyclonal primary antibody 
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exhibits a specific staining for PGRMC1 in cumulus cells, germinal vesicle, granulosa 
cells, theca layer and endothelial cells when compared with the goat polyclonal primary 
antibody. Final magnification = 400X, scale bar = 50 µm. 
 
Figure 7. Immunohistochemical localization of PGRMC1 in bovine ovarian cortex. 
PGRMC1 is localized in primordial, primary and secondary follicles (A), in early antral 
follicles (B) and in antral follicles (C). Note that the expression of PGRMC1 is more 
evident in the granulosa cells closer to the oocyte, in the GV and in the internal theca 
layer. PGRMC1 was detected in the endothelial cells (Arrows) and in the germinal 
epithelium at the ovarian surface (D, Arrowhead). No immunoreactivity was seen in 
negative control where incubation with the primary antibody had been omitted (E). Final 
magnification = 200X, scale bar = 50 µm. 
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Figure 8. Immunohistochemical localization of PGRMC1 in bovine corpora lutea 
during the luteal and follicular phase of the estrus cycle. 
During the luteal phase (A) PGRMC1 is localized in the cytoplasm of the luteal cells 
displaying an heterogeneous signal, varying from intense to weak to completely absent. 
During the follicular phase (B) PGRMC1 is detected as a weak signal in the cytoplasm of 
most of the luteal cells. In both phases PGRMC1 is expressed in the endothelial cells and 
is weakly detected in the nucleus of the luteal cells. Final magnification = 200X, scale bar 
= 50 µm. 
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Figure 9. Immunohistochemical localization of PGRMC1 in bovine oviduct and 
uterus. 
PGRMC1 is expressed in the different tracts of the oviduct, infundibulum (A), ampulla (B) 
and isthmus (C) in luminal epithelium, in the muscle layers (ml) and in the vessels 
(Arrowheads). In the uterus PGRMC1 is localized in luminal (E) and glandular (F) 
epithelium, in the muscle layers (ml) and in the endothelial cells (Arrowheads). Note that 
the nuclear staining of epithelial cells is intense both in oviduct and uterus. No 
immunoreactivity was seen in negative control where incubation with the primary antibody 
had been omitted (D). Final, scale bar = 50 µm. 
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DISCUSSION 
 To the best of our knowledge, this is the first study that describes PGRMC1 
immunolocalization in various parts of bovine reproductive system. In the ovary, PGRMC1 
has been detected in germinal epithelium, granulosa cells, theca cells, and oocyte in all 
stages of folliculogenesis, in agreement with previous studies conducted in rat [28]. Data 
from the literature indicate that, in the ovary, PGRMC1 is continuously and highly 
expressed during fetal development in rat and cow and it has been suggested that 
PGRMC1 participates through a progesterone-dependent mechanism to the process of 
primordial follicle assembly [127, 138]. 
 In this study, PGRMC1 was intensely localized in the GV of oocytes. This confirms 
our previous immunofluorescence study in the oocyte where PGRMC1 was restricted in 
the GV after follicle isolation [132]. In the oocyte, PGRMC1 has a role in oocyte 
maturation, which may be specifically related to the mechanism of chromosomes 
segregation. However, other Authors were unable to detect PGRMC1 in the bovine oocyte 
[133] while it was detected in the surrounding granulosa cells. This difference may be due 
to the different sensitivity of the antibody used and to the shorter incubation time 
employed in the previous study (3 h). As indicated in our study, the polyclonal rabbit anti-
PGRMC1 antibody showed a much higher sensitivity respect to the polyclonal goat anti-
PGRMC1 antibody and the titration assay demonstrated that only high concentrations of 
the polyclonal goat anti-PGRMC1 antibody were able to detect a specific signal by 
western blot and immunohistochemistry under our experimental conditions. 
  Our observations in the ovary and corpus luteum support previous studies where 
the expression of PGRMC1 was found in granulosa and luteal cells in human [101], 
mouse [122], rat [28], pig [123] and cow [124, 139]. PGRMC1 positivity in endothelial cells 
of the corpus luteum reported in previous study on PGRMC1 expression in cow [139] was 
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also confirmed by our observations. 
 Furthermore, in the present work, the expression of PGRMC1 in the corpus luteum 
was found to be influenced by the stage of the estrous cycle. In the luteal phase, 
PGRMC1 was intensely localized in the cytoplasm while in the follicular phase a weak 
PGRMC1 signal was detected in the cytoplasm of most of the cells. This stage-specific 
localization of PGRMC1 could be explained through the functional status of the corpus 
luteum. Beside its possible involvement in steroid synthesis in the active corpus luteum, 
the ability of PGRMC1 in promoting luteal cell viability by mediating progesterone anti-
apoptotic action was demonstrated [101].  
 PGRMC1 was detected among the proteins that were differentially expressed in 
the human endometrium during the menstrual cycle [113]. This study showed that 
PGRMC1 protein was more highly present in the proliferative (luteal) than the secretory 
(follicular) phase and immunostaining data revealed that it was confined to the stromal 
component of proliferative phase endometrium. Analogously, microarray profiling of 
progesterone-regulated endometrial genes during the rhesus monkey secretory phase 
showed a down regulation of PGRMC1 [140]. These findings were confirmed also in mice 
[115] where PGRMC1 expression was up-regulated in the stromal compartment of the 
uterus from estrus to metestrus and reduced during diestrus. In the bovine, our study 
showed that PGRMC1 localization in the oviducts and in the uterus horns, was similar in 
the ipsilateral or the contralateral organs and was irrespective of the stage of the estrous 
cycle. This difference between species may be explained by the different technique 
adopted since the immunochemical detection of the protein must be confirmed by a 
quantitative analysis. Moreover, the level of the transcript must be determined in order to 
assess whether or not the phase-independent localization of PGRMC1 observed in this 
study, in bovine oviduct and uterus, is accompanied by a phase-independent PGRMC1 
transcript level. 
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 In the present study we did not observe differences in PGRMC1 localization in the 
uterus between the luteal and follicular phases. However, we do not exclude that these 
differences could arise during pregnancy. In fact, a decrease in PGRMC1 has been 
observed in human myometrium during term or preterm labor, where PGRMC1 down-
regulation might contribute to the ‘functional withdrawal' of progesterone’s action and shift 
the balance to a state of increased uterine contractility [141]. Moreover, PGRMC1 was 
described in the human and mouse placenta and associated membranes with the most 
abundant expression in smooth muscle of the placental vasculature, villous capillaries and 
the syncytiotrophoblast suggesting that this protein functions in events important to early 
pregnancy, including cellular differentiation, modulation of apoptosis and steroidogenesis 
[115]. Therefore, the study of PGRMC1 localization and expression of PGRMC1 during 
pregnancy in the cow would be of particular interest since dissimilarities between species 
could be due to the different involvement of the endometrium in the process of 
placentation in these species. Rodents and primates are characterized by an 
haemochorial placenta while cows have a synepitheliochorial placenta. Further studies 
are needed in order to confirm this hypothesis. 
 In conclusion, the present immunohistochemical study showed that PGRMC1 is 
located in various compartments of the bovine female reproductive organs. Despite some 
difference in PGRMC1 expression have been reported in human and mouse, our data 
suggest that with the exception of the corpora lutea, PGRMC1 localization does not seem 
to be differentially regulated during different stage of the estrus cycle. However, a 
quantitative study must be conducted in order to clarify the phase-independency of 
PGRMC1 expression in this species. 
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9. Part II 
 
Progesterone Receptor Membrane Component-1 Expression and Putative Function 
in Bovine Oocyte Maturation, Fertilization and Early Embryonic Development 
 
Summary 
Although mRNA that encodes progesterone receptor membrane component-1 
(PGRMC1) is present in mammalian oocytes, nothing is known about either PGRMC1’s 
expression pattern or function in oocytes during maturation, fertilization and subsequent 
embryonic development. Since in somatic cells PGRMC1 associates with the mitotic 
spindle, we hypothesized that PGRMC1 is involved in oocyte maturation (meiosis). 
Western blot analysis confirmed the presence of PGRMC1 in bovine oocytes. The present 
study also shows that PGRMC1 is present at the GV- and MII-stage oocyte and is 
associated with male and female pronucleus formation of the zygote and is highly 
expressed in blastocysts. A more detailed examination of PGRMC1 localization using 
confocal imaging demonstrated that in germinal vesicle (GV) stage oocytes, PGRMC1 
was concentrated throughout the GV but did not localize to the chromatin. With the 
resumption of meiosis in vitro, PGRMC1 concentrated in the centromeric region of 
metaphase I chromosomes, while in anaphase I/telophase I stages the majority of 
PGRMC1 concentrated between the separating chromosomes. At the metaphase II stage, 
PGRMC1 re-associated with the centromeric region of the chromosomes. A colocalization 
study demonstrated that PGRMC1 associated with the phosphorylated form of Aurora 
kinase B, which localizes to the centromeres at metaphase. Finally, PGRMC1 antibody 
injection significantly lowered the percentage of oocytes that matured and reached the 
metaphase II stage after 24 h of culture. The majority of the PGRMC1 antibody-injected 
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oocytes arrested in the prometaphase I stage of meiosis. Furthermore in most of the 
PGRMC1 antibody-injected oocytes, the chromosomes were disorganized and scattered. 
Taken together these data demonstrate that PGRMC1 is expressed in bovine oocytes and 
its localization changes at specific stages of oocyte maturation. These observations 
suggest an important role for PGRMC1 in oocyte maturation, which may be specifically 
related to the mechanism by which chromosomes segregate. 
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INTRODUCTION 
Progesterone receptor membrane component-1 (PGRMC1) is an evolutionary 
conserved protein that is involved in regulating numerous biological functions [4]. Recently 
PGRMC1 was detected among the proteins of the mitotic spindle [129], suggesting a role 
for it in mitosis. Interestingly, PGRMC1 is also expressed in bovine [130], rat [28] and 
human oocytes [128]. Moreover, the mRNA that encodes PGRMC1 is present in bovine 
oocytes at a very high level similar to that of actin [130]. In spite of its high level of 
expression, little is known about PGRMC1 and oocyte function. Since PGRMC1 is present 
in mitotic spindle [129], it could be directly involved in regulating oocyte maturation 
(meiosis). 
In mammalian ovaries, oocytes are arrested in prophase of the first meiotic 
division (i.e. germinal vesicle stage) until the gonadotropin surge induces meiosis in 
oocytes of preovulatory follicles. Nuclear meiotic maturation of oocytes includes 
condensation of chromosomes and the sequential progression through prometaphase I, 
metaphase I, anaphase I and telophase I. The meiotic progression then arrests at 
metaphase II [142]. This sequence of meiotic events also occurs in vitro. For example in 
cows, fully-grown oocytes extracted from follicles larger than 2 mm are capable of 
resuming meiosis in vitro with approximately 90% of the oocytes reaching metaphase II 
[143]. Regardless of whether meiosis occurs in vivo or in vitro, this process requires the 
precise coordination between the chromosomes and the tubulin-based meiotic spindle. 
To guarantee the coordinated interaction between the chromosomes and the 
meiotic spindle, the activity and localization of various spindle-associated proteins is 
strictly regulated [144]. One important spindle-associated protein is Aurora B (AURKB). 
AURKB is a protein kinase that is a component of the chromosomal passenger complex 
(CPC), which also consists of an inner centromere protein, INCENP, which binds AURKB 
[145]. During mitosis, AURKB plays a critical role in chromosome-microtubule interactions 
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[146]. This kinase is localized to the kinetochores from prophase to metaphase and 
relocates to the central spindle and the mid-body in cytokinesis [147]. The altered 
expression AURKB is implicated in defects of centrosome function, spindle assembly, and 
chromosomal instability [148, 149]. 
AURKB is also expressed in mammalian oocytes [150-153]. It gradually becomes 
phosphorylated on Thr-232 during oocyte maturation. Phosphorylation of AURKB 
activates this kinase and leads to the phosphorylation of Histone H3 and the gradual 
condensation of chromatin [150, 152, 154]. Moreover, altered AURKB activity increases 
the risk in chromosome congression failure, non-disjunction and aneuploidy in mammalian 
oocytes [155]. 
Since PGRMC1 is highly expressed in bovine oocytes and zygotes [130] and it is 
localized on the mitotic spindle [129], we hypothesized that PGRMC1 is involved in 
meiosis. The present studies were designed to determine the role of PGRMC1 in oocyte 
meiotic division by monitoring its 1) localization during oocyte in vitro maturation, 
fertilization and early development, 2) relationship to changes in the activity of AURKB 
and 3) function by injecting an antibody to PGRMC1 into oocyte prior to in vitro 
maturation. 
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MATERIAL AND METHODS 
Oocyte Collection and Culture 
All the chemicals used in this study were purchased from Sigma Chemical 
Company (St. Louis, MO) except for those specifically mentioned. Bovine ovaries were 
recovered at the abattoir (INALCA JBS S.p.A., Ospedaletto Lodigiano, LO, IT 2270M CE, 
Italy) from pubertal females subjected to routine veterinary inspection and in accordance 
to the specific health requirements stated in Council Directive 89/556/ECC and 
subsequent modifications. Ovaries were transported to the laboratory within 2 hours in 
sterile saline (NaCl, 9 g l-1) maintained at 26°C. All subsequent procedures, unless 
differently specified, were performed at 35-38°C. Cumulus-oocyte complexes (COCs) 
were retrieved from mid-sized antral follicles (2-6 mm) with a 16-gauge needle mounted 
on an aspiration pump (COOK-IVF, Brisbane QLD, Australia). COCs were washed in 
TCM199 supplemented with HEPES buffer (20 mM HEPES, 1790 units/L Heparin and 
0.4% of bovine serum albumin (BSA)) and examined under a stereomicroscope. Only 
COCs medium-brown in color, with five or more complete layers of cumulus cells with 
oocytes with finely granulated homogenous ooplasm were used.  
Groups of 25-30 COCs were in vitro matured in TCM-199 supplemented with 0.68 
mM L-glutamine, 25 mM NaHCO3, 0.4% BSA fatty acid free, 0.2 mM sodium pyruvate and 
0.1 IU/ml of recombinant human FSH (r-hFSH, Gonal-F, Serono, Rome, Italy) in 
humidified air under 5% CO2 at 38.5°C as previously described [156]. Oocytes were 
mechanically separated from cumulus cells either just after collection from ovaries 
(immature oocytes at GV stage) or after 4, 8, 12, 16, 20 and 24 h of culture. 
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In Vitro Fertilization and Embryo Culture 
After 24h of in vitro maturation, oocytes were fertilized as previously described 
[156]. Briefly, the contents of a straw of cryopreserved bull spermatozoa (CIZ, S. Miniato 
Pisa, Italy) was thawed and cells separated on a 45-90% Percoll gradient. Sperms were 
counted and diluted to a final concentration of 0.5x106 spermatozoa/ml in fertilization 
medium that was a modified Tyrode’s solution (TALP) supplemented with 0.6% (w/v) BSA 
fatty acid free, 10 µg/ml heparin, 20 µM penicillamine, 1 µM epinephrine, and 100 µM 
hypotaurine. COCs and sperms were incubated for 18 hours at 38.5° C under 5% CO2 in 
humidified air. After in vitro fertilization, presumptive zygotes were washed and cumulus 
cells were removed by vortexing for 2 min in 500 µl of a modified synthetic oviduct fluid 
(SOF, [157]) supplemented with 0.3% (w/v) BSA fraction V, fatty acid free, MEM essential 
and non-essential aminoacids, 0.72 mM of sodium pyruvate, and buffered with 10 mM of 
HEPES and 5 mM of NaHCO3. Presumptive zygotes were rinsed and transferred in 
embryo culture medium, which was SOF buffered with 25 mM of NaHCO3, supplemented 
with MEM essential and non-essential aminoacids, 0.72 mM of sodium pyruvate, 2.74 mM 
of myo-inositol, 0.34 mM of sodium citrate and with 5% of calf serum (Gibco, Invitrogen, 
San Giuliano Milanese, Milan, Italy). Incubation was performed at 38.5° C under 5% CO2, 
5% O2 and 90% N2 in humidified air. Zygotes and blastocyst stage embryos were 
collected after 18 and 196 hours post insemination, respectively [158]. 
 
 Western Blot Analysis 
Freshly isolated COCs were denuded by vortexing in 500 µl of TCM199 
supplemented with 20 mM HEPES and 5% calf serum (Gibco, Invitrogen, Life 
Technologies, Carlsbad, CA, USA) for 2 min at 35 Hz. Oocytes (500-700 per extracts) and 
aliquots of 50 mg of ovarian cortex were homogenized in lysis buffer [10 mM Tris-Cl, pH 4, 
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1% w/v NP-40, 150 mM NaCl, imM EDTA, 0.2% Zwitterion], which was supplemented with 
complete protease inhibitor cocktail and incubated for 1 hour on ice then centrifuged at 
14000 g for 15 min. The supernatant was then mixed with 4X SDS-Laemmli loading buffer 
and extensively boiled for 15 minutes. After centrifugation for 5 min at 14000 g, each cell 
extract was loaded onto 12% acrylamide gel and transferred to nitrocellulose. The 
nitrocellulose was then incubated with 5% nonfat dry milk powder overnight at 4° C to 
saturate nonspecific sites. The nitrocellulose blot was incubated with polyclonal rabbit 
anti-PGRMC1 (Prestige antibodies, Sigma) for 2 hours at room temperature at a dilution 
of 1:500. Western blots were processed using a horseradish peroxidase-conjugated anti-
rabbit secondary antibody (1:2000) for 45 minutes at room temperature and developed 
using HRP Immuno-Blot Assay kit (Bio-Rad Laboratories, Segrate, Milan, Italy). 
 
Immunofluorescence Staining 
Indirect immunofluorescence was carried out to evaluate the cellular localization of 
PGRMC1, Aurora Kinase B (AURKB) and Aurora Kinase B phosphorylated on Threonine 
232 (phospho-Thr232 AURKB) in oocytes at different stages of meiosis (See Table 2). All 
the oocytes and the zygotes were freed of cumulus cells by vortexing. Then the zona 
pellucida was removed from oocyte, zygotes and embryos using 0.5% pronase as 
previously described [159]. After being washed three times in phosphate buffered saline 
containing 0.1% polyvinylalchol (PBS-PVA), the oocytes, the zygotes and the embryos 
were fixed in 4% paraformaldehyde in PBS for 15 min at 37°C, then transferred to 4°C for 
the next 45 min. The fixed oocytes, zygotes and embryos were washed three times with 
PBS-PVA and permeabilized with 0.3% Triton-X 100 in PBS for 10 min at room 
temperature. Non-specific binding was blocked by incubating the samples in 10% donkey 
serum, 1% BSA in PBS for 30 min at room temperature. The samples were then 
incubated with the primary antibody overnight at 4°C. PGRMC1 immunolocalization was 
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carried out using a rabbit polyclonal anti-PGRMC1 antibody (Prestige Antibodies by 
Sigma). For the co-localization studies, the oocytes were incubated either with a solution 
of rabbit polyclonal anti-PGRMC1 antibody and mouse monoclonal anti-AURKB antibody 
(Abcam, Cambridge, UK) or with a solution of mouse monoclonal anti-AURKB antibody 
and rabbit polyclonal anti-phospho-Thr232 AURKB antibody (BioLegend, San Diego, CA, 
USA). All the primary antibodies were diluted 1:50 in PBS containing 1% BSA. After being 
washed three times in PBS-PVA for 10 min each, the oocytes were incubated with TRITC 
labeled donkey anti rabbit antibody (dilution 1:100; Vector Laboratories, Inc., Burlingame, 
CA, USA) or, for the colocalization experiment, with a solution of Alexa Fluor 488 labeled 
donkey anti mouse antibody (dilution 1:500; Invitrogen, Life Technologies, Carlsbad, CA, 
USA) and TRITC labeled donkey anti rabbit antibody for 30 min at room temperature. The 
samples were washed 3 times in PBS-PVA and mounted on slides in the antifade medium 
Vecta Shield (Vector Laboratories Inc., Burlingame, CA, USA) supplemented with 1 µg/ml 
DAPI. Samples were analyzed on a Nikon Diaphot epifluorescence microscope or a Nikon 
C1si confocal laser-scanning microscope (Nikon Corp. Tokyo, Japan). In each 
experiment, negative controls were performed by adding an equal concentration of rabbit 
IgG (Vector Laboratories) or omitting the primary antibodies and did not reveal any 
staining. 
 
PGRMC1 Blocking Antibody Injection Study 
The anti-PGRMC1 antibody (Prestige Antibodies by Sigma) was spin-dialyzed and 
concentrated using 10kD Millipore Ultrafree 0.5 PBGC filter unit (Millipore Corp., Bedford, 
MA, USA). GV stage oocytes within their cumulus cell complexes were injected with 15-35 
pl of a 1.2 mg/ml stock solution of anti-PGRMC1 antibody in PBS. This resulted in a final 
concentration of 0.15-0.30 µM of antibody in the oocyte. The injected volume represented 
approximately 1.5-3% of oocyte volume. As control a group of COCs in each experiment 
 65 
was injected with an equal volume of rabbit IgG (Vector Laboratories) dissolved in PBS at 
the same concentration or PBS only. The procedure was carried out as previously 
described in mouse [160, 161] and adapted to bovine oocyte volume. A microinjection 
apparatus (Narishige CO LTD, Tokyo, Japan) was used to guide the holding and injecting 
micropipettes into a 50 µl drop of TCM199-HEPES buffer covered with mineral oil. The 
injecting pipette was connected to a FemtoJet (Eppendorf Srl, Milano, Italy) that allowed 
the injection of minute quantities of solution. After being injected, COCs were washed in 
TCM199-HEPES buffer and matured in vitro for 24 h as above described. After the 
maturation time, the oocytes were freed of cumulus cells and fixed in 500 µl of 60% 
Methanol in PBS for 30 min at 4°C. The oocytes were stained with 0.5 mg/ml of Propidium 
Iodide to assess the stage of meiotic progression by observation at 200-400x under 
fluorescence microscopy [156]. 
 
Statistical Analysis 
All experiments were replicated at least three times. Observations from all the 
experiments were pooled. The images shown in each figure are representative. The 
actual number of oocytes at each stage of maturation that were analyzed is provided in 
the legend of each figure. Differences in maturation rate in the PGRMC1 blocking 
antibody injection study were analyzed by Chi square test. Probabilities of less than 0.05 
were considered statistically significant. 
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RESULTS 
PGRMC1 Expression in Oocytes, Zygotes and Embryos 
 As shown in Figure 10, western blot analysis demonstrated that PGRMC1 was 
specifically detected in bovine oocytes as a ≈ 26 kDa protein. Having established that this 
antibody specifically detects bovine PGRMC1, it was utilized to localize PGRMC1 in 
bovine oocyte undergoing meiosis in vitro. Note that under culture conditions employed in 
these studies, GV stage oocyte resume meiosis with 93% of the oocytes reaching 
metaphase II by 24 h of culture (Table 2). The rate of in vitro fertilization and blastocyst 
development was respectively 89.5% and 37.3%. In a preliminary study, PGRMC1 was 
localized at the time of collection or after in vitro maturation, in vitro fertilization and 
embryo culture, and then observed in epifluorescence microscopy. As shown in Figure 11, 
PGRMC1 was present within GV in immature oocytes and associated with the MII plate of 
in vitro matured oocytes. After IVF, PGRMC1 was associated with the female and the 
male pronucleus. At the blastocyst stage, virtually all the blastomeres showed positive 
staining for PGRMC1. 
Having confirmed that PGRMC1 was present in bovine oocytes and embryos, changes in 
the localization of PGRMC1 during oocyte maturation was examined in more detail 
utilizing confocal microscopy. This analysis revealed that PGRMC1 associates with the 
metaphase II chromosomes at distinct focal points (Figure 12), which suggests that 
PGRMC1 localizes to the centromere. 
As shown in Figure 11 PGRMC1 was not detectable in the ooplasm. In fact, the 
fluorescent staining of the cytoplasm in the IgG control was similar to that observed in the 
PGRMC1 antibody immunostained group (compare Figure 11 A and B). 
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Table 2. Sequential meiotic stages during bovine oocyte in vitro maturation. 
 
*Time in culture. Values in bold indicate the highest percentage of oocytes in specific 
stages of meiosis for each time in culture. Pro I, prophase I; Promet I, Prometaphase I; 
Met I, metaphase I; Ana I, anaphase I; Telo I, telophase I; Met II, metaphase II. 
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Figure 10. Detection of PGRMC1 in bovine oocytes. Western blot analysis showing 
PGRMC1 expression in bovine oocytes. A western blot using lysate prepared from bovine 
ovarian cortex, conducted in the absence of the PGRMC1 antibody, is shown as a 
negative control (-) while a western blot using this lysate conducted in the presence of the 
PGRMC1 antibody, is shown as a positive control (+). Western blot using lysate prepared 
from bovine oocytes is shown in lane 3. Representative blots from three independent 
experiments are shown. 
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Figure 11. PGRMC1 localization in prophase I (GV stage) (a), metaphase II oocyte (b), 
pronuclei stage (c) and blastocyst stage embryo (d). Note that PGRMC1 appears to 
associate with germinal vesicle in immature oocyte and with the metaphase chromosomes 
in MII oocyte. In (b) the insert shows the magnified metaphase II plate. In zygotes, 
PGRMC1 is associated with male and female pronucleus and is localized in the 
blastomeres up to the blastocyst stage of development. Representative images in 
epifluorescence are shown. 
This immunocytochemical analysis was conducted on a total of 98 oocytes at the following 
stages: 39 in prophase I; 27 in metaphase II I; 17 in pronuclear; 15 in blastocyst. 
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Figure 12. PGRMC1 localization in metaphase II stage oocytes. Polar and lateral views 
are shown. Images were obtained by scanning the sample on z-axis at 0.2 µm of 
thickness throughout the plane of focus containing the chromosomal equatorial plane. The 
z-series were then projected to obtain a three dimensional image using the software 
provided by Nikon Microscopes Inc. PGRMC1 appears to associate with the metaphase 
chromosomes at precise focal points, consistent with a centromeric localization. The 
localization of PGRMC1 in 90 oocytes metaphase II was examined. Representative 
images are shown.  
 
PGRMC1 Expression in Oocytes During Meiosis in vitro and PGRMC1 and AURKB 
Colocalization 
To test this assumption, PGRMC1 was colocalized with AURKB, which is known to 
associate with proteins that comprise the centromere at metaphase [145]. This study 
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demonstrated that in prophase I (GV stage) oocytes, PGRMC1 and AURKB were highly 
expressed within the GV, but neither protein associated with the chromatin. At 
prometaphase I (i.e. after GV breakdown), both proteins began to associate with the 
chromosomes and this association was more evident in metaphase I oocytes. During 
anaphase I/telophase I stages, both proteins dissociated from the chromosomes and 
concentrated in the midzone and the midbody of the separating chromosomal plates. At 
anaphase I, these two proteins colocalized throughout the midzone. During telophase, 
some AURKB colocalized to PGRMC1 at the center of the midbody between the 
chromosomal plates. Interestingly some AURKB at the periphery of the midbody was not 
colocalized with PGRMC1. PGRMC1 and AURKB appeared to localize to the spindle pole 
in some oocytes. However, this was not consistently observed and its functional 
significance, if any, remains to be determined in further studies. Finally at the metaphase 
II stage, both PGRMC1 and AURKB again colocalized to the centromeric region of the 
chromosomes (Figure 13). 
In a third study, the relationship between the AURKB and the Thr-232 
phosphorylated (active) form of AURKB, was assessed. This study illustrated that AURKB 
began to associate with the chromatin in all of the prometaphase I oocytes, but the active 
form of AURKB was only barely detectable in about half of these oocytes. By metaphase 
I, staining for phosphorylated AURKB was readily detectable in all the oocytes and 
remained so up to the metaphase II stage (Figure 14). Importantly after GV breakdown, 
PGRMC1 was always concentrated to those subcellular compartments where the active, 
phosphorylated form of AURKB was present. This was particularly evident at the 
telophase I stage (compare Figure 13 and 14). 
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Figure 13. (legend on next page) 
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Figure 13. Colocalization of PGRMC1 and AURKB during bovine oocyte maturation. 
Representative confocal images showing PGRMC1 and AURKB localization at the 
indicated meiotic stages, from the prophase I (GV stage) to the metaphase II. Images 
were cropped to show the area containing the chromatin. PGRMC1 (red) and AURKB 
(green) immunostaining are merged with DAPI (DNA; blue) counterstained image to 
visualize the specific protein-chromosomes associations. In the right column PGRMC1 
and AURKB images are merged to reveal sites of their colocalization (orange). Note that 
the images of anaphase I and telophase I are in lateral view in order to better illustrate the 
relationship between PGRMC1 and AURKB at the midzone and the midbody. The images 
of metaphase I and metaphase II are shown in a polar view in order to better illustrate the 
relationship between PGRMC1, AURKB and the chromosomes. This 
immunocytochemical analysis was conducted on a total of 199 oocytes at the following 
stages: 21 in prophase I; 17 in prometaphase I; 39 in metaphase I; 38 in anaphase I; 34 in 
telophase I and 50 in metaphase II. 
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Figure 14 (legend on next page) 
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Figure 14. Colocalization of AURKB and phosphorylated AURKB during bovine oocyte 
maturation. Representative confocal images showing the relationship between AURKB 
and the active (phosphorylated) form of AURKB (pAURKB) from the prophase I (GV 
stage) to the methaphase II stages of meiosis. pAURKB (red) and AURKB (green) 
immunostaining are merged with DAPI (DNA; blue) counterstained image. In the right 
column pAURKB and AURKB images are merged to reveal sites of their colocalization 
(orange). Images were cropped to show the area containing the chromatin. The inserts in 
the prometaphase stage are images of pAURKB staining. This immunocytochemical 
analysis was conducted on a total of 239 oocytes (38 in prophase I; 18 in prometaphase I; 
43 in metaphase I; 41 in anaphase I; 53 in telophase I and 46 in metaphase II. 
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PGRMC1 and Oocyte Maturation 
To begin to assess the role of PGRMC1 on oocyte maturation, GV stage oocytes 
within their cumulus cell mass were injected with antibody to PGRMC1 while controls 
were injected with either IgG or PBS. After 24h, only 22% (n=68) of the oocytes injected 
with the PGRMC1 antibody progressed to metaphase II compared to 74% (n=39; p < 
0.05) and 68% (n=43; p < 0.05) of PBS or IgG-injected oocytes, respectively (Figure 15A). 
A high proportion of PGRMC1 antibody-injected oocytes (57.4%) arrested in 
prometaphase I stage. Some of the PGRMC1 antibody-injected oocytes progressed 
beyond prometaphase I as 5.8 (n=4), 8.8 (n=6) and 22% (n=15) reached metaphase I, 
anaphase/telophase I and metaphase II respectively, with most of these possessed 
chromosomes that were disorganized and scattered throughout the ooplasm (compare 
Figures 15C with 15B). 
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Figure 15. Effect of PGRMC1 antibody injection on bovine oocyte maturation. * indicates 
a value that is significantly difference (p<0.05) from either PBS or IgG. After 24 h of 
culture, oocytes were stained with propididum iodide (red) to reveal the chromosomes. 
Panel B shows chromosomes that are precisely arranged in a metaphase plate (i.e. 
control) while panel C shows a bovine oocyte 24 h after being injected with PGRMC1 
antibody. Note that the chromosomes are not aligned and disorganized. 
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DISCUSSION 
The present study confirms and expands a previous mRNA-based observation 
[130] by demonstrating that PGRMC1 is present in bovine oocytes as a ≈ 26 kDa protein. 
This is consistent with PGRMC1 western blots obtained from lysates of other organs and 
cell types such as porcine liver [40], human and rat granulosa and luteal cells [28, 101], 
mouse and human smooth muscle, uterus and placenta [115]. The present study also 
shows that PGRMC1 is present at the GV- and MII-stage oocyte and is associated with 
male and female pronucleus formation of the zygote and is highly expressed in 
blastocysts. Specifically prior to fusion of the pronuclei, PGRMC1 localizes to several foci 
that appear to be within ‘nucleolar precursor bodies (NPBs)’ [162]. NPBs have been 
observed at the pronuclei of bovine zygotes and apparently function in nucleolus 
formation [163]. Moreover, NPBs are the sites of ribosomal RNA synthesis with rRNA 
encoding polypeptides they comprise ribosomes and therefore are essential for the 
synthesis of proteins that ultimately direct embryonic development [164]. 
Because fertilization and embryonic development are dependent on successful 
oocyte maturation, the present work focused more intensely on changes in PGRMC1 after 
the resumption of meiosis. These studies, utilizing confocal microscopy, reveal that 
PGRMC1 starts to concentrate on the chromatin. This becomes more evident at 
metaphase I, where PGRMC1 is restricted to the centromeric region of bivalent 
chromatids. During anaphase I and telophase I, PGRMC1 dissociates from the 
chromosomes and localizes in the midzone and midbody, respectively. At metaphase II, 
PGRMC1 again concentrates at the centromeric region of the chromosomes. These 
temporal changes in the localization of PGRMC1 during oocyte maturation suggest an 
important role for PGRMC1 in the process that governs meiotic progression of the oocyte. 
That PGRMC1 localizing to the chromosomes is important, is supported by the 
finding that PGRMC1 colocalizes with AURKB at specific stages of the oocyte meiotic 
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progression. It is well known that AURKB is expressed during oocyte meiosis in cows 
[153], mice [151, 152, 155] and pigs [150]. In general, our observations on AURKB are in 
agreement with the known changes in the localization of AURKB that occur during oocyte 
meiotic division. The one notable exception is that Uzbekova and co-authors [153] failed 
to detect AURKB within the GV, while our studies did. The use of a different AURKB 
antibody and/or a different fixation protocol likely account for the differences observed in 
these two studies. 
While the issue of AURKB within the GV remains to be resolved, it is important to 
appreciate that AURKB is a serine/threonine protein kinase that regulates many 
processes during mitosis and meiosis [155, 165, 166]. In meiosis, AURKB is involved in 
chiasma resolution and its activation (i.e. phosphorylation on Thr-232) is correlated with 
cytokinesis and first polar body formation [155, 165]. In addition treatment with a 
pharmacological inhibition of AURKB results in the failure to extrude the first polar body. 
Furthermore in porcine oocytes, AURKB activity increases after prometaphase I reaching 
a maximum at metaphase I and thereafter is maintained until metaphase II [150]. The 
present studies are consistent with these observations and further reveal that during 
telophase I AURKB localizes within the spindle midbody. Interestingly not all of the 
AURKB within the spindle midbody is active. Rather only the AURKB at the center of the 
midbody is active (phosphorylated). Interestingly the active fraction of AURKB appears to 
colocalize with PGRMC1. This implies that both PGRMC1 and AURKB are involved in the 
mechanism by which asymmetric cytokinesis occurs during first polar body formation. 
The fact that PGRMC1 only appears to colocalize with active AURKB raises the 
issue of whether PGRMC1 is essential for the activation of AURKB. Recently a 
fluorescence resonance energy transfer (FRET)-based assay was used to assess 
phospho-Thr232 AURKB activity in anaphase HeLa cells. Similar to our observations in the 
bovine oocycte, this study revealed that most of the AURKB activity localized to the center 
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of the midbody [167]. These authors suggest that the spindle or spindle-associated 
proteins are responsible for activating AURKB. Although a previous study indicated that 
PGRMC1 is associated with the mitotic spindle [129], a role of PGRMC1 in activating 
AURKB during mitosis and meiosis can be only hypothesized and considerably more 
studies must be conducted to resolve this issue.  
In addition, PGRMC1 may be involved in meiotic events that precede polar body 
formation, since the present data demonstrate that PGRMC1 associates with chromatin 
and colocalizes with AURKB at metaphase I and metaphase II. AURKB is a component of 
the chromosomal passenger complex (CPC), which in part consists of the inner 
centromere protein, INCENP, to which AURKB is physically associated [145]. 
Furthermore, altered AURKB expression has been suggested to increase the frequency of 
non-disjunction and aneuploidy in mammalian oocytes [155] while an over-expression 
prevents chromosome misalignment during meiosis of mouse oocytes [151]. Collectively, 
these findings are consistent with the concept that the interaction between PGRMC1 and 
AURKB plays a role in AURKB’s ability to promote homologous chromosome alignment 
and segregation.  
This concept is supported by two observations. First, the present work 
demonstrates that PGRMC1 concentrates at foci on the chromatin of prometaphase I-
staged oocytes and at this time, AURKB starts to be phosphorylated. As meiosis 
progresses, both PGRMC1 and the phosphorylated form of AURKB become concentrated 
on the centromeric region. Since pharmacological inhibition of AURKB activity leads to 
abnormal chromosome congression and alterations in the formation of the chromosomal 
plate [152, 155], this implicates that PGRMC1-AURKB interaction is involved in the 
mechanism by which chromosomal separation is mediated. 
The second and probably more important observation supporting a functional role 
for PGRMC1 in oocyte meiotic maturation is provided by the PGRMC1 antibody injection 
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study. In this study, PGRMC1 antibody injection at GV stage results in the improper 
positioning of the chromatin, affecting the ability of the chromosomes to condense 
properly and resolve bivalents. While these observations support a role for PGRMC1 in 
meiosis, they also demonstrate the need to define the exact nature of the relationship 
between PGRMC1 and active AURKB. 
The present studies also supports the hypothesis that changes in the level of 
PGRMC1 expression or its genetic structure could predispose oocytes to undergo 
abnormal meiotic division, which would lead to errors in chromosome segregation and 
ultimately aneuploid embryos. Interestingly, there are at least two conditions in women in 
which PGRMC1 is altered. The first is a reduction in the level of PGRMC1 expression 
observed in women with an X;autosome translocation (i.e. [t(X;11)(q24;q13)]). This X-
chromosome translocation likely depletes one copy of PGRMC1, thereby accounting for 
the reduced level of PGRMC1 in these women [6]. The second condition involves a single 
base mutation in which the histidine at residue 165 is changed to arginine. Although this 
mutation does not change the level of PGRMC1 expression, it does reduce its functional 
activity by approximately 50% [6]. Both of these genetic alterations in PGRMC1 are 
detected in woman with premature ovarian failure [6]. Whether these alterations in 
PGRMC1 expression or genetic structures adversely affects the functional capacity of the 
oocyte remains to be determined.  
 In summary these data demonstrate that PGRMC1 is expressed in bovine 
oocytes, zygotes and blastocysts. Our data also suggest an important role for PGRMC1 in 
oocyte maturation that may be specifically related to the mechanism by which 
chromosomes segregate and the first polar body extruded. These studies also imply that 
PGRMC1 and AURKB interact at specific points in the meiotic cascade to insure that 
errors in spindle formation, chromosome segregation and cytokinesis do not occur. These 
possibilities are currently under investigation. 
 82 
10. Part III 
 
Oocytes isolated from dairy cows with reduced ovarian reserve have a high 
frequency of aneuploidy and alterations in the localization of Progesterone 
Receptor Membrane Component-1 and Aurora Kinase-B 
 
SUMMARY 
 Oocytes isolated from cows of reproductive age with reduced antral follicle counts 
(AFC) have a diminished capacity of embryonic development, which may be related to 
alterations in the mechanism that directs the proper segregation of chromosomes. Since 
we demonstrated that Progesterone Receptor Membrane Component 1 (PGRMC1) is 
involved in chromosome congression and metaphase II (MII) plate formation, the present 
study was designed to determine 1) if the decrease in oocyte developmental competence 
observed in dairy cows with a reduced AFC is due to a higher incidence of aneuploidy and 
2) whether alterations in PGRMC1 contributes to the incidence of aneuploidy. Oocytes 
from ovaries with reduced AFC and aged-matched controls were matured in vitro and the 
occurrence of aneuploidy determined as well as the mRNA level and localization of 
PGRMC1. Although oocytes from ovaries with reduced AFC were capable of undergoing 
meiosis in vitro, these oocytes showed a 3-fold increase in aneuploidy compared to 
oocytes isolated from control ovaries (P<0.05). Although Pgrmc1 mRNA levels were not 
altered, PGRMC1 and AURKB failed to localize to precise focal points on MII 
chromosomes of oocytes from ovaries with reduced AFC. Further, when oocytes of 
control ovaries were cultured with an inhibitor of AURKB activity, their MII plate was 
disrupted and PGRMC1 was not properly localized to the chromosomes. These results 
suggest that alterations in PGRMC1 and/or AURKB localization account in part for the 
increased aneuploidy and low development competence of oocytes from ovaries with 
reduced AFC.
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INTRODUCTION  
 Premature ovarian senescence as estimated by a reduced number of antral follicle 
count (AFC) is a common cause of infertility in both woman and cattle [10, 168]. Low AFC 
has been described in women in peri-menopausal period [169, 170] as well as in young 
infertile and subfertile women affected by premature ovarian failure [9, 10] suggesting that 
the factors that reduce follicular reserve also affect the quality of the remaining oocytes 
[171]. 
 Recently, we demonstrated that about 5% of culled dairy cows 4-8 years old had a 
reduced AFC compared to aged-matched controls [11]. Moreover, oocytes isolated from 
low AFC ovaries had limited developmental capability compared to aged-matched controls 
[11, 172, 173]. The mechanism responsible for the reduced developmental competence of 
these oocytes is still unclear and it may be related to alterations in the mechanism that 
directs the proper segregation of chromosomes.  
 During oocyte meiosis, the cell division machinery must function sequentially 
during a reductive (meiosis I) and equational (meiosis II) cell division to ultimately produce 
a haploid oocyte that can be fertilized and give rise to the next generation. Errors in this 
process can result in aneuploidy, which can have adverse reproductive outcomes such as 
infertility, miscarriages, and birth defects [174-177].  
Aurora kinase B (AURKB) is a component of the chromosomal passenger 
complex, which together with the spindle assembly checkpoint ensures faithful 
chromosome segregation [144, 178]. During mitosis, AURKB plays a critical role in 
chromosome-microtubule interactions [146]. This kinase is localizes to the kinetochores 
from prophase to metaphase and relocates to the central spindle and the mid-body during 
cytokinesis [147]. Alterations in the localization of AURKB are implicated in defects of 
centrosome function, spindle assembly and chromosomal instability [148, 149]. 
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 Interestingly, Progesterone Receptor Membrane Component 1 (PGRMC1) and the 
phosphorylated (active) form of AURKB co-localize at the centromere of chromosomes in 
MII oocytes [179]. Moreover, an injection of a PGRMC1 antibody impairs the ability of 
oocytes to successfully mature and causes abnormalities in chromosomal segregation 
such as chromosomes misalignment and disorganization [179], suggesting that PGRMC1 
plays a key role in chromosomes congression.  
 Therefore, the present study was designed to determine 1) if the decrease in 
oocyte developmental competence observed in dairy cows with a reduced AFC is due to a 
higher incidence of aneuploidy and 2) whether alterations in PGRMC1 and AURKB 
localization contributes to the incidence of aneuploidy.  
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MATERIAL AND METHODS 
Oocyte Collection and Culture 
All the chemicals used in this study were purchased from Sigma Chemical 
Company (St. Louis, MO) except for those specifically mentioned. Bovine ovaries were 
recovered at the abattoir (INALCA S.p.A., Ospedaletto Lodigiano, LO, IT 2270M CE, Italy) 
from pubertal females (4-8 years old) subjected to routine veterinary inspection and in 
accordance to the specific health requirements stated in Council Directive 89/556/ECC 
and subsequent modifications. As previously stated [180] ovaries were transported at 
26°C and all subsequent procedures were performed at 35-38°C. From each slaughtered 
animal, ovaries were isolated and classified into the two previously described categories 
[11, 172, 173]: ovaries with reduced AFC (<10 mid-sized antral follicles of 2-6 mm) and 
age-matched controls (>10 follicles of 2-6 mm).  
Cumulus-oocyte complexes (COCs) were retrieved from mid-sized antral follicles 
(2-6 mm) and examined under a stereomicroscope. Only COCs medium-brown in color, 
with five or more complete layers of cumulus cells with oocytes with finely granulated 
homogenous ooplasm were used [180].  
Groups of 15-30 COCs were in vitro matured in TCM-199 supplemented with 0.68 
mM L-glutamine, 25 mM NaHCO3, 0.4% BSA fatty acid free, 0.2 mM sodium pyruvate and 
0.1 IU/ml of recombinant human FSH (r-hFSH, Gonal-F, Serono, Rome, Italy) in 
humidified air under 5% CO2 at 38.5°C as previously described [156].  
 
Aneuploidy Assessment 
 Karyotype analysis was performed as previously described [181] with some 
modifications and all chromosome preparation procedure was performed at 26°C, unless 
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otherwise stated [182]. After IVM, oocytes were mechanically separated from cumulus 
cells by 5 minutes vortexing. Only oocytes with polar body were selected for karyotype 
analysis and incubated for 20 minutes. Each oocyte was placed in a hypotonic solution 
(0.075 M KCl) for 20 minutes to induce nuclear swelling. Subsequently oocytes were 
gently transferred to a well with the first fixative (methanol:acetic acid:distilled water, 5:1:4, 
v/v) for 5 minutes. Then they were dropped from 5 cm to a wet slide heated at 37°C and 
45 degree sloped. When the drop was spread out, the oocytes were covered with the 
second fixative (methanol: acetic acid, 3:1, v/v) and then the slides were immersed in a 
coplin jar containing the second fixative for 10 minutes. After that they were transferred to 
a second jar containing the third fixative (methanol : acetic acid : distilled water, 3:3:1, v/v) 
for 1 minute then the slides were slowly removed and air-dried overnight. Chromosomes 
staining was performed by a 4% GIEMSA solution for 15 minutes. Then the slides were 
extensively washed with tap and distilled water and air-dried at 37°C for 30 minutes and 
mounted. Slides were examined by light microscopy (40X magnification) and 
chromosomes number for each metaphase plate was counted using Leica CW4000 Karyo 
software (Leica Microsystems, Wetzlar, Germany). Two investigators examined each 
chromosome preparation. 
 
Real Time PCR for PGRMC1 
 The levels of Pgrmc1 mRNA expression were assessed in oocytes from ovaries 
with Low AFC and from ovaries of age-match control group, at the time of collection from 
the follicle (GV stage) and after 24 h of IVM (MII stage) using a real-time multiplex PCR 
assay. COCs were collected and cultured as described above and cumulus cells were 
mechanically removed by the use of vortex. Denuded oocytes were stored in RNAlater 
solution (Ambion, Life Technologies) until assayed. Total RNA was extracted from groups 
of 20 oocytes using the RNeasy Plus Mini Kit (Quiagen) according to the manufacturer 
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instruction. Total RNA was then retro-transcribed with oligo dT using the M-MLV Reverse 
Transcriptase System (Invitrogen, Life Technologies). A total amount of cDNA equivalent 
to 6 oocytes was used in each amplification reaction. Reactions were run in triplicates on 
4 different biological replicates for each experimental group. Amplification was performed 
with specific primers and TaqMan probes for bovine Pgrmc1 (NCBI RefSeq 
NM_001075133.1; Forward primer: 5’-CTGGAAGAGATGCATCCAGA -3’; Reverse 
primer: 5’- GAGATCCCAGTCACTCAGGGT-3’; probe: 5’ d FAM-
TCCGACCTCACTCCTGCCCA- BHQ-1 3’) and β actin (NCBI RefSeq: NM_173979.3; 
Forward primer: 5’- CACTCTTCCAGCCTTCCTTC -3’; Reverse primer: 5’- 
GGATGTCCACGTCACACTTC -3’,probe: 5’ CAL Fluor Gold 540- 
TGCCACAGGACTCCATGCCC- BHQ-1 3’) using an CFX96 PCR Thermal Cycler (Bio-
Rad, Hercules, CA, USA). Beta Actin was used as internal standard and relative level of 
Pgrmc1 mRNA was determined using the ΔCT method.  
 
Immunofluorescence Staining 
 Indirect immunofluorescence was carried out to evaluate the cellular localization of 
PGRMC1 and AURKB in MII stage- paraformaldehyde fixed oocytes, as previously 
described [132, 159]. The samples were incubated overnight at 4°C either with a rabbit 
polyclonal anti-PGRMC1 (dilution 1: 50, Prestige Antibodies by Sigma) or a mouse 
monoclonal anti-AIM-1 antibody (dilution 1: 50, Aurora B and Ipl1-like midbody associated 
protein; BD Transduction Laboratories, Franklin Lakes, NJ, USA). Secondary antibodies 
used were: TRITC labeled donkey anti rabbit antibody (dilution 1:100; Vector 
Laboratories, Inc., Burlingame, CA, USA) or with Alexa Fluor 488 labeled donkey anti 
mouse antibody (dilution 1:500; Invitrogen, Life Technologies, Carlsbad, CA, USA) for 30 
min at room temperature. The samples were mounted on slides in the antifade medium 
Vecta Shield (Vector Laboratories) supplemented with 1 µg/ml DAPI. In each experiment 
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negative controls were performed by omitting the primary antibodies and did not reveal 
any staining. 
 Samples stained for PGRMC1 were analyzed on a C1si confocal laser-scanning 
microscope (Nikon Corp. Tokyo, Japan) with a X60 objective. Z-stacks were compiled with 
0.25 µm intervals encompassing the entire MII plate. PGRMC1 localization was classified 
as regular when PGRMC1 localized at the centromeric region of each chromosome or 
irregular when presented one or more of the following aspects: more than one point on a 
chromosome, shape different from the punctuated, not in the centromeric region, lack of 
PGRMC1. Samples stained for AURKB were analyzed on an epifluorescence microscope 
(Eclipse E600, Nikon) equipped with a X60 objective, a digital camera and a 
deconvolution software (NIS elements Imaging Software, Nikon). AURKB localization was 
classified as regular or irregular according to the criteria adopted for PGRMC1 
localization. 
 
ZM447439 Treatment  
 ZM447439 was dissolved in dimethyl sulfoxide (DMSO) at 10 mM and stored in 
aliquots at -20°C. Appropriate concentrations were prepared in culture medium so that the 
final concentration of DMSO never exceeded 1 µl/ml. This DMSO concentration has been 
previously reported to be not effective on bovine oocyte maturation and fertilization [179, 
183]. 
In a first set of experiments GV stage oocytes were cultured in presence of the Aurora 
Kinase activity inhibitor ZM447439 (Tocris, Ellisville, MO, USA) in concentrations ranging 
from 0 to 10 µM. After 24 h, COCs were freed of cumulus cells, fixed and stained with 
DAPI 1 µg/ml. Samples were analyzed on a epifluorescence microscope (Eclipse E600, 
Nikon) for polar body extrusion, maturation rate and chromosome alignment. In a second 
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set of experiments GV stage oocytes were cultured in presence of 5 µM ZM447439, then 
fixed and stained for PGRMC1 immunolocalization, as described above.  
All the MII stage oocytes analyzed, either following 3-dimension reconstruction of the 
metaphasic plate by confocal microscopy or with conventional fluorescence microscopy, 
that failed to align all their chromosome along the equator of the metaphasic plate were 
classified as “misaligned”, as previously described [151]. 
 
Statistical analysis 
 All the experiments were repeated three to five times. Observations from all the 
experiments were pooled. Statistical significance was determined by Fisher's exact test. 
Values of p <0.05 were considered significant.  
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RESULTS 
 Maturation rates were similar between oocytes isolated from reduced AFC (89%, 
67/75) and age-match control ovaries (94%, 119/127). Importantly, karyotype analysis 
(Figure 16) indicated that although oocytes from ovaries with reduced AFC were capable 
of undergoing meiosis in vitro, these oocytes showed a 3-fold increase in aneuploidy 
compared to oocytes isolated from aged-matched control ovaries (Figure 16A). The 
analysis of karyotypes detected both hyperploid and hypoploid (Figure 16B) oocytes 
within each group but there was not a difference in the percentage of hypoploid or 
hyperploid oocytes between the reduced AFC and age-match control groups. Moreover, 
no specific chromosome-dependence aneuploidy was detected. 
 Because PGRMC1 plays a role in the formation of the MII plate, Pgrmc1 mRNA 
levels and the colocalization of PGRMC1 with AURKB was monitored at the GV and at the 
MII stage. Pgrmc1 mRNA levels were not altered in either GV- or MII-staged oocytes of 
ovaries with reduced ovarian reserve when compared to the age-match control group 
(Supplemental Figure 1). Moreover, PGRMC1 and AURKB colocalized at the centromeric 
region of MII stage bovine oocyte, as confirmed in a control experiment that corroborated 
our previous observations (Figure 17). However, PGRMC1 failed to localize to precise 
focal points on MII chromosomes in a significantly higher percentage of oocytes isolated 
from reduced AFC ovaries compared to oocytes of age-match control ovaries (Figure 18 A 
and 18 B). Similarly, the percentage of oocytes in which AURKB failed to properly localize 
on the MII chromosomes was significantly higher in oocytes from ovaries with reduced 
AFC compared to oocytes isolated from ovaries of aged-matched controls (Figure 19 A 
and 19 B).  
 To further investigate the relationship between PGRMC1 and the AURKB function 
during oocyte maturation, oocytes isolated from control ovaries were matured in the 
presence of increasing concentrations of ZM447439 [151], an AURKB inhibitor [184]. At 
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all concentrations tested (1 to 10 µM), the percentages of oocytes that reached MII with 
polar body extrusion after 24 hr of treatment did not differ from control oocytes (Table 4), 
which is consistent with a previous report [155]. However at the concentrations of 5 and 
10 µM, a significantly higher percentage of oocytes exhibited misaligned chromosomes 
when compared to controls (Table 3). In another set of experiment, when oocytes of age-
match control ovaries were cultured with 5 µM of ZM447439 the chromosomal 
organization of the MII plate was disrupted (Figure 20) and PGRMC1 was not properly 
localized to the chromosomes (Table 4) even though the ability of oocytes to mature was 
not affected (Table 4).  
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Table 3: Effect of ZM447439 on meiotic progression, polar body extrusion and 
chromosome alignment. 
 
ZM447439 
Concentration 
N MII (%) PB Extrusion 
(% of MII) 
Misalignment 
(% of MII) 
0 55 47 (85.5) 47 (100) 14 (29.8)a 
1 µM 53 41 (77.4) 40 (97.6) 17 (41.5)a 
2 µM 58 42 (72.4) 42 (100) 20 (47.6)a 
5µM 54 39 (72.2) 37 (94.9) 32 (82.1)b 
10 µM 56 42 (75.0) 38 (90.5) 39 (92.9)b 
 
N represents the number of oocytes analyzed in each group. Data were analyzed by 
Fisher’s exact test. a, b: values with different superscripts within columns are significantly 
different (a, b: p<0.0001). 
 93 
 
Table 4: Effect of ZM447439 on PGRMC1 localization. 
 
ZM447439 
Concentration 
N MII (%) Misalignment 
(% of MII) 
Irregular PGRMC1 
localization (% of MII) 
0 21 20 (95.2) 10 (50)a 9 (45)a 
5 µM 26 22 (84.6) 20 (90.1)b 20 (90.1)b 
 
N represents the number of oocytes analyzed in each group. Data were analyzed by 
Fisher’s exact test. a, b: values with different superscripts within columns are significantly 
different (a, b: p=0.0001). 
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Figure 16. A: Percentage of aneuploidy in oocytes isolated from control and Low AFC 
ovaries. Data were analyzed by Fisher's exact test (asterisk indicates p<0.05). B: 
Representative images of hypoploid, normal and hyperploid karyograms. 
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Supplemental Figure 1. PGRMC1 mRNA expression levels in Control and Low AFC 
oocytes. Relative PGRMC1 mRNA expression in GV stage (A) and MII stage (B) Control 
and Low AFC oocytes. Data were calculated by the ΔCT using beta Actin as internal 
standard. 
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Figure 17: PGRMC1 and AURKB co-localization on centromere of chromosomes in 
metaphase II control oocytes. Red: PGRMC1; green: AURKB. Bar 10 µm. 
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Figure 18: PGRMC1 localization in oocytes isolated from Low AFC and age-match 
control ovaries. A: percentage of oocytes isolated from control and low antral follicle count 
ovaries showing regular and irregular PGRMC1 localization. Data were analyzed by 
Fisher's exact test (asterisk indicates p<0.05). B: representative images of regular and 
irregular localization of PGRMC1 in MII stage oocytes. Blue: DNA; Red: PGRMC1. Bar 10 
µm.  
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Figure 19: AURKB localization in oocytes isolated from Low AFC and age-match control 
ovaries. A: percentage of oocytes isolated from control and low antral follicle count ovaries 
showing regular and irregular AURKB localization. Data were analyzed by Fisher's exact 
test (asterisk indicates p<0.05) B: representative images of regular and irregular 
localization of AURKB in MII stage oocytes. Blue: DNA; Green: AURKB. Bar 5 µm. 
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Figure 20: PGRMC1 localization in oocytes of control ovaries treated with the AURKB 
inhibitor ZM447439. Representative images of regular and irregular localization of 
PGRMC1 in MII stage oocytes. Blue: DNA; Red: PGRMC1. Bar 10 µm. 
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DISCUSSION 
 During oocyte meiotic division, defects in spindle formation and/or function can 
generate chromosome instability and aneuploidy, a condition that is the major cause of 
defective early embryonic development, miscarriages and birth defects [7]. While errors in 
chromosomal segregation can occur at any time during embryonic development, 
aneuploidy occurs frequently during oocyte meiotic division with about 20% of human 
oocytes having chromosomal segregation errors [185]. While aneuploidy is an important 
cause of reproductive wastage, the factors that promote chromosomal segregation errors 
have not been clearly defined. In mice the frequency of chromosomal segregation errors 
(i.e. aneuploidy) increases with the gradual depletion of ovarian follicle reserve, which is 
associated with increasing chronological age [8]. The present work also reveals a 
relationship between ovarian reserve and chromosomal segregation errors by 
demonstrating that oocytes, collected from cows with reduced ovarian reserve (i.e. 
reduced AFC) have a 3-fold increase in aneuploidy compared with oocytes collected from 
cows with a normal or high AFC. In contrast to the well known age-related increase in 
chromosomal segregation errors, the present study examined animal of the same 
approximate age. Therefore, there may be some defect(s) within oocytes isolated from 
ovaries with premature decreases in ovarian reserve that are distinctly different from age-
related alterations.  
 As evidence of functional molecular alterations in oocytes harvested from ovaries 
with reduced ovarian reserve, the present study reveals that PGRMC1 fails to properly 
associate with the MII chromosomes of oocytes isolated from cows with a reduced ovarian 
reserve. This inability to target PGRMC1 to the MII chromosomes occurs even through 
Pgrmc1 is expressed at levels similar to that of oocytes with normal ovarian reserve. 
Moreover, failure of PGRMC1 to associate with the MII chromosomes likely accounts, at 
least in part, for their higher incidence of aneuploidy, since disrupting PGRMC1’s action 
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with an antibody to PGRMC1 interferes with the formation of the MII plate [132].  
Although PGRMC1 influences the formation of the MII plate, its mechanism of 
action is not known. PGRMC1 co-localizes with the active (Thr-232 phosphorylated) form 
of AURKB. AURKB is gradually activated during oocyte maturation and phosphorylates 
essential proteins that are involved in chromosome segregation such as the meiotic 
cohesin protein Rec8 [186], which functions to hold sister chromatids together [187].  
Although AURKB colocalizes with PGRMC1, a functional relationship between 
these two proteins has not been established. The present study demonstrates that the 
AURKB inhibitor, ZM447439, causes chromosome misalignment and alters PGRMC1’s 
localization at centromeres in oocytes obtained from ovaries with high or normal AFC. 
This implies that AURKB activity is required to properly localize PGRMC1 to the MII 
chromosomes. However, some caution must be exercised in drawing this conclusion, 
since ZM447439 could inhibit AURKA or AURKC as well as AURKB. Importantly all the 
concentrations tested, ZM447439 did not inhibit maturation and polar body extrusion, 
which are known to be dependent on AURKA [151, 155]. This argues that ZM447439 
does not inhibit AURKA even at the maximum concentration used in this study (10 µM). 
Interestingly, the expression of the AURKC isoform is negligible in immature and mature 
bovine oocytes [153]. It is likely then that even though the inhibition of AURKC cannot be 
completely excluded, the biological effect of ZM447439 should be principally ascribed to 
the inhibition of AURKB and it is therefore logical to conclude that AURKB is required for 
PGRMC1 to properly localize to the MII chromosomes.  
 Because our data indicate that Pgrmc1 mRNA levels were not reduced in oocytes 
of ovaries with reduced AFC, the hypothesis that PGRMC1 regulates oocyte maturation 
through the association with AURKB raises the question as to whether post-translational 
modification of PGRMC1 could be regulated by AURKB. Several proteomic-based studies 
indicate that PGRMC1 can be phosphorylated at several serine residues [188, 189]. In 
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fact, phosphorylated PGRMC1 is associated with the mitotic spindle [5, 129]. Since 
AURKB is a serine/threonine kinase [190], it is possible that AURKB either directly or 
indirectly phosphorylates PGRMC1 with phosphorylation directing PGRMC1 to the MII 
chromosomes. This hypothesis is currently being assessed. 
In addition to phosphorylation, recent studies reveal that PGRMC1 is sumoylated 
in ovarian cells [191]. Sumoylation is an important post-translational modification in which 
small ubiquitin-related modifier (SUMO) proteins are covalently attached to lysine residues 
in their substrate proteins. Substrate modification by sumoylation can alter protein–protein 
interactions, change protein intracellular localization or direct changes in the activities of 
the protein to which SUMO is attached [192]. Importantly, sumoylation may play an 
essential role in regulating mouse oocyte meiosis, since SUMO1 or more likely proteins 
that are covalently coupled to SUMO1 localize to the spindle poles in prometaphase I, 
metaphase I and II, and around the separating chromosomes in anaphase I and telophase 
I, while SUMO2/3 is mainly concentrated near the centromeres [193]. These observations 
are consistent with the concept that part of mechanism that localizes PGRMC1 to MII 
chromosomes involves both phosphorylation and sumoylation.  
 In conclusion, our data is supports the hypothesis that PGRMC1 and AURKB 
interaction during oocyte meiosis plays an essential role in the process of chromosome 
segregation, because the inhibition of AURKB causes changes in the localization of 
PGRMC1 and alterations in the MII chromosomal plate. Moreover, alteration in the 
localization of PGRMC1 and AURKB could account in part for the increased aneuploidy 
and low development competence of oocytes of ovaries isolated from cows with reduced 
ovarian reserve. 
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11. CONCLUSIONS 
Reproductive efficiency in dairy cows is decreasing worldwide. The root cause of the 
declining fertility is probably a combination of a variety of physiological and management 
factors that have an additive effect on reproductive efficiency [2]. These factors include 
increasing in milk production and herd size, greater use of confinement housing, labor 
shortages and higher inbreeding percentages. In addition, the reproductive physiology of 
dairy cattle has also changed in response to genetic selection for milk production. 
Compared with traditional dairy cows, modern dairy cows have longer intervals to first 
ovulation, a higher incidence of anestrus and abnormal luteal phases, lower blood 
progesterone and IGF-I concentrations, higher incidence of multiple ovulations and 
twinning rates as well as greater embryonic loss [1]. Declining fertility represents an 
obstacle in maintaining profitability of dairy farms [1-3]. It has been estimated that a slight 
increase in pregnancy rates results in a significant increase in profitability that could make 
the difference in whether a family farm remains in operation [194, 195]. These findings 
suggest that defining the factors and mechanisms that contribute to oocyte and embryo 
quality is essential for improving female fertility. In particular, basic knowledge of which 
proteins within the oocyte regulate meiosis, oocyte fertilizability and developmental 
potential would be advantageous. 
Starting from these observations, our studies were conducted to test the hypothesis that 
PGRMC1 is one of the key factors that regulate mammalian oocyte quality and therefore 
female fertility. Initial indications that PGRMC1 participates in progesterone signaling in 
the reproductive system come from studies in which PGRMC1 expression was silenced 
using siRNA in ovarian cells. These experiments demonstrated that Progesterone’s ability 
to inhibit ovarian cells from undergoing apoptosis in vitro is dependent on PGRMC1 [119], 
indicating that PGRMC1 plays an essential role in promoting the survival of ovarian cell in 
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vitro. This led us to start our investigations on the function of PGRMC1 in bovine fertility.  
Initial experiments were conducted to determine the presence and localization of 
PGRMC1 in various compartments of the bovine female reproductive organs, during the 
follicular and luteal phases of the estrous cycle. Importantly, these studies revealed the 
presence of PGRMC1 in the nucleus of bovine oocytes. Further studies revealed that 
PGRMC1 is present in both GV- and MII-stage oocyte, is associated with male and female 
pronuclei in the zygote and is highly expressed in the blastocysts, with typical localization 
at each of these stages. 
Since fertilization and embryonic development are mainly dependent on the completion of 
oocyte maturation, we focused our attention on PGRMC1’s role during this important step. 
Our localization as well as our functional data suggest an important role of PGRMC1 in 
oocyte maturation that may be specifically related to the mechanism by which 
chromosomes segregate and the first polar body extruded. Moreover, we have started to 
elucidate the mechanism by which PGRMC1 could act as a regulator of oocyte meiosis. In 
fact we demonstrated not only that PGRMC1 co-localize with the active form of AURKB, 
but also that the activities of these two molecules may be somehow related. In fact, 
inhibition of AURKB causes changes in the localization of PGRMC1 and alterations in the 
MII chromosomal plate. Furthermore, our data suggest that alteration in the localization of 
PGRMC1 and AURKB could account in part for the increased aneuploidy and low 
development competence of oocytes of ovaries isolated from cows with reduced ovarian 
reserve. 
In conclusion, the present study raise important questions regarding the role of 
PGRMC1 in the regulation of oocyte maturation and the loss of fertility of dairy cows. 
Despite the mechanism through which PGRMC1 regulates these processes is still 
unknown and remains to be deeply investigated, our data indicate that functional 
alterations of PGRMC1 could impair meiosis and reduce development competence of 
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oocytes. Finally, understanding these mechanisms in cattle could provide insight into how 
these processes are regulated in other species, including humans. 
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